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Abstract 
Over one-third of the world’s population is at risk for infection with dengue virus 
(DENV), a mosquito-borne virus that can cause a severe febrile disease. There are no 
specific treatments available for dengue infection, and much remains unknown about how 
DENV interaction with the host cell leads to a successful infection. This dissertation 
examines DENV entry using small molecule inhibitors and mutagenesis of the envelope 
(E) protein, the major protein on the viral surface. 
This work grew from our initial observation that small molecule GNF-2 is capable of 
lowering DENV yield when present at two separate points during DENV infection. 
Treatment of infected cells with GNF-2 post-entry significantly lowered DENV yield, 
most likely due to GNF-2’s documented activity against Abl kinase. However, we also 
observed that treatment of virus inocula with GNF-2 prior to cellular infection 
significantly lowered DENV yield. We discovered that GNF-2 bound directly to the 
dengue virion and co-localized with DENV envelope protein shortly after cellular 
infection. Using GNF-2 as a scaffold, we performed a structure-activity relationship 
study and identified twenty-one compounds that have similar or increased potency as 
GNF-2 when pre-incubated with virus. Using a subset of compounds from this study, we 
demonstrated that they block completion of DENV fusion in vitro, suggesting that the   iv 
   
compounds inhibit DENV entry by preventing the completion of viral fusion inside 
cellular endosomes. 
In experiments complementing the mechanism of action studies, we selected for 
inhibitor-resistant virus by passaging virus in the presence of small molecules. We 
identified a single point mutation in the envelope protein located in the domain I/II 
interface that enhanced viral entry and conferred resistance to virus particles against 
select compounds in a single-cycle reporter virus system. Further examination of this E 
protein “hinge region” found that mutations in this area may affect both release and entry 
of reporter virus particles. The work presented in this dissertation may inform the design 
of future small molecule inhibitors of DENV as well as increase our understanding of 
how point mutations in the DENV E protein can influence viral entry and other steps of 
the viral life cycle. 
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Chapter 1: Introduction 
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SIGNIFICANCE 
There are over 50 million cases of dengue fever worldwide each year, and almost 
forty percent of the world’s population is at risk for infection by the causative agent, 
dengue virus (DENV) (WHO, 2012). DENV is transmitted by the bite of infected 
mosquitoes, predominantly Aedes aegypti, and there are currently no specific treatments 
or therapies available. Despite its global presence, much remains unknown about basic 
biological processes of the virus and its life cycle, as historically most research has 
focused on patient care. One possible avenue to blocking dengue virus infection may be 
to inhibit viral entry, as has been done for HIV using T-20, a peptide that binds and 
inhibits viral glycoprotein-mediated membrane fusion (Kilby et al., 1998).  
In broader efforts to use chemical biology to interrogate cellular factors and processes 
required for successful DENV infection, we conducted a screen of known kinase 
inhibitors and identified several small molecules that had potent activity against DENV in 
cell culture (Chu and Yang, 2007). Subsequently, while exploring the function of GNF-2, 
a small molecule of intracellular Abl kinases, we found that GNF-2 inhibited DENV 
infectivity when incubated with virus inoculum prior to cellular infection. The work 
presented in this study explores the activity of GNF-2 and its derivatives as DENV entry 
inhibitors. Small molecule inhibitors have traditionally been useful as molecular probes 
in studying the function of their respective targets. Here, we have approached the 
mechanistic study of GNF-2 and related compounds blocking viral entry as a means by 
which to discover more about the DENV entry process and the structure and function of 
the DENV envelope protein, which is responsible for mediating all steps of viral entry. 
This knowledge may inform the development of future antivirals.    
 
 
3 
INTRODUCTION 
Dengue virus as an emerging global human pathogen 
In the past fifty years, dengue virus (DENV) has become a major global human 
pathogen; the World Health Organization (WHO) estimates that there are currently 
between 50 and 100 million dengue fever cases worldwide each year, and over 2.5 billion 
people are at risk for contracting the disease. Cases of dengue fever have increased 
alarmingly over the past forty to fifty years in both frequency and geographic spread. 
Prior to 1970, only nine countries had reported dengue outbreaks, while by 2010 over 100 
countries were considered to have endemic dengue (WHO, 2012). While the recent 
increase may be due to increased reporting and surveillance, evidence suggests that the 
number of dengue cases worldwide is actually under-reported (Amarasinghe et al., 2011; 
WHO, 2012). The explosion of DENV cases has been attributed to increased urbanization 
and the accompanying spread of the primary carrier of DENV, the mosquito species 
Aedes aegypti. Mosquitoes are infected with DENV when they bite an infected human 
with a high viral load, and, after a short incubation period during which the virus works 
its way to the salivary glands, the insects transmit the virus for the rest of their lives 
(Gubler, 1976). It has also been shown that DENV can be transmitted vertically from 
mosquitoes to their progeny (Rosen, 1987). 
 
Dengue pathogenesis 
Dengue fever is the most common form of disease caused by DENV. It is 
characterized by a high fever, joint pain, rash, and flu-like symptoms that can last from 
two to seven days and typically appear four to seven days after contracting the virus  
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(Lindenbach and Rice, 2001). Although rarely fatal, particularly if patients are given 
supplemental fluids, it can be a painful and debilitating disease, so much that it is 
commonly referred to as “breakbone fever.” A more serious presentation of dengue virus 
infection is severe dengue, a form of the disease in which a patient can experience 
bleeding, fluid buildup, and plasma leakage. This form of dengue, which has a 20-30% 
mortality rate if left untreated, is the leading cause of hospitalization and death among 
children in many endemic areas (WHO, 2012). 
There are four serotypes of DENV (DENV1, DENV2, DENV3, and DENV4) that are 
defined by their antigenic differences (Calisher et al., 1989). It is not clear if certain 
DENV serotypes cause more severe illness (Balmaseda et al., 2006; Vaughn et al., 2000), 
but it is known that surviving a specific serotype provides life-long immunity to that 
serotype while providing only short-term protection against other serotypes (Lindenbach 
and Rice, 2001). In fact, surviving one serotype increases the risk of developing severe 
dengue if a person subsequently is infected with a different serotype (Alvarez et al., 
2006). This increased risk of severe disease is likely due to a phenomenon known as 
antibody-dependent enhancement (ADE), in which antibodies developed against one 
serotype bind to but do not neutralize virions of a different DENV serotype. These 
antibody-coated virus particles experience enhanced binding and infection of cells 
expressing Fc receptors, such as macrophages, which then leads to higher viremia in 
patients and more severe manifestations of the disease (Peiris and Porterfield, 1979). 
ADE is of increasing concern to the public health community as DENV spreads around 
the globe; as of 2004, many regions of the world reported all four serotypes circulating in 
the population (Mackenzie et al., 2004). Due to the risk of ADE, vaccine development for  
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DENV is a major challenge, as vaccines must elicit a protective antibody response 
against all four serotypes. 
Despite the rapid global spread of dengue virus and large risk of infection to the 
world’s population, there is a dearth of knowledge about many basic DENV processes. 
Historically, most research has focused on patient health, symptoms, outbreaks, 
genotyping, or epidemiology. Thus, while the need for specific treatments and 
therapeutics is urgent as the virus continues to spread to new areas of the world, the 
design of such antivirals is severely hampered by lack of knowledge about how DENV 
successfully carries out infection and replication. 
 
Dengue virus life cycle 
Dengue virus is a member of the Flaviviridae family, which includes other human 
pathogens such as yellow fever virus (YFV), Hepatitis C virus (HCV), and the closely 
related West Nile virus (WNV). Dengue virions contain a positive-sense, single-stranded 
RNA genome, approximately 11kb in length, that associates with the small viral capsid 
(C) protein (Lindenbach and Rice, 2001). The genome contains short non-coding regions 
at both the 3’ and 5’ end that have been shown to be important for both translation and 
replication (Holden et al., 2006; Kinney et al., 2005). The genome is translated as one 
polyprotein that is co- and post-translationally cleaved into three structural (C, prM, and 
E) and seven nonstructural proteins (NS1, NS2A/B, NS3, NS4A/B, and NS5).  
DENV has a lipid envelope and mature virions are approximately 50 nm in diameter. 
There are 180 copies of the envelope (E) protein on the virion surface that form 90 
homodimers arranged in a tight herringbone structure [Figure 1-1, (Kuhn et al., 2002)].   
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Figure 1-1. Organization of the dengue virion. Schematic of the mature dengue virion. 
(Left) Cutaway showing organization of structural proteins on the exterior of the virion 
with the genomic RNA inside. (Right) Herringbone arrangement of E protein 
homodimers on the virion surface. Used with permission from ViralZone 
(www.expasy.org/viralzone, Swiss Institute of Bioinformatics). 
    
 
 
7 
These E protein dimers mediate binding to cells, after which the virus is taken up by 
clathrin-mediated endocytosis into endosomes (Acosta et al., 2008; van der Schaar et al., 
2008), where the low pH triggers viral fusion (Gollins and Porterfield, 1986). The viral 
genome is released into the cytoplasm, where it undergoes translation and replication in 
membrane-associated complexes in the perinuclear region (Westaway et al., 1997). The 
polyprotein is cleaved by viral and cellular proteases and nascent virions are assembled 
by budding into the endoplasmic reticulum (Mackenzie and Westaway, 2001). New 
virions are exocytosed through the cellular secretory pathway, during which prM, a 
chaperone protein that protects premature triggering of the E protein, is cleaved by furin 
(Stadler et al., 1997) and the E protein rearranges into homodimers (Stiasny et al., 1996). 
 
DENV envelope protein 
The DENV envelope (E) protein is the major glycoprotein present on the exterior of 
the mature virion and mediates all aspects of viral entry. E consists of three domains, a 
stem region, and a transmembrane domain. The pre-fusion and post-fusion crystal 
structures of DENV2 soluble envelope protein, containing domains I-III, have been 
solved and are similar in appearance to other flavivirus E proteins [Figure 1-2; (Modis et 
al., 2003, 2004)]. Domain III contains an immunoglobulin-like region that is believed to 
be the receptor-binding domain, while finger-like domain II contains the fusion loop at its 
distal end (Mukhopadhyay et al., 2005). The stem region, although not solved as part of 
the crystal structures, is thought to consist of two highly-conserved amphipathic helices 
and a loop that lie close to the viral membrane in the pre-fusion conformation and play an  
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Figure 1-2. Crystal structures of the DENV2 envelope (E) protein. (A) Pre-fusion E 
protein homodimer as viewed from above virion surface. Domains I, II, and III of a single 
monomer are shown in in red, yellow, and blue, respectively. Stem region of E is not 
shown. (B) Side view of the E homodimer. The virion membrane would be located 
underneath the structure in this orientation. (C) Post-fusion E trimer. Note the large 
movement of domain III in a monomer relative to the pre-fusion dimer. PDB IDs: 1OAN 
[dimer; (Modis et al., 2003)], 1OK8 [trimer; (Modis et al., 2004)].    
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important role in creation and stabilization of the post-fusion E trimer (Zhang et al., 
2003a).  
Throughout the viral life cycle, the E protein undergoes a series of conformational 
rearrangements and protein associations. Initially expressed as part of the polyprotein, E 
is translocated into the ER lumen and quickly forms a heterodimer with prM, which acts 
as a chaperone protein and is necessary for proper folding of E (Konishi and Mason, 
1993). These E/prM heterodimers appear as trimer spikes on the surface of newly 
assembled, immature virions (Zhang et al., 2003b). As the virus passes through the low 
pH of the trans-Golgi network, the E protein rearranges into dimers and the pr peptide is 
cleaved by the cellular protease furin but remains associated (Yu et al., 2008), protecting 
the fusion loop to prevent premature triggering of the post-fusion trimer rearrangement 
(Zhang et al., 2004). The remnant of prM, M, is a small (~8kD) protein that sits 
underneath the E homodimer on the virion surface and consists of an alpha helix that 
remain membrane associated (Zhang et al., 2003a). As the dengue virion is exocytosed 
from the cell, the pr peptide is released, and the E protein is found in its pre-fusion, 
homodimer, herringbone arrangement on the virion surface (Figure 1-1) (Zhang et al., 
2003a).  
Mature virions bind to cells via interactions with unknown receptor(s), although 
several classes of surface proteins, including DC-SIGN (Tassaneetrithep et al., 2003) and 
glycosaminoglycans (Chen et al., 1997), have been suggested to play supporting roles. 
Once bound to cells, the virus is taken up into clathrin-coated pits and transported to 
endosomal compartments where viral fusion occurs (van der Schaar et al., 2008). The 
exact trigger for DENV fusion remains unclear, as a study using flavivirus tick-borne  
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encephalitis virus (TBEV) showed that protonation of a key histidine residue was 
responsible for triggering fusion (Fritz et al., 2008), while another study in WNV showed 
that no single histidine residue on E was necessary for fusion initiation (Nelson et al., 
2009). The optimal pH for triggering DENV fusion is also unknown; WNV fusion has 
been reported at pH levels as high as 6.9 (Moesker et al., 2010), although the threshold 
for DENV is typically agreed to be around 6.3 (Lee et al., 1997; Nelson et al., 2009). 
 
DENV fusion 
The DENV E protein is a class II viral fusion protein. The crystal structures of the 
pre-fusion dimer and post-fusion trimer have been solved, revealing several large 
conformational changes (Figure 1-2) (Modis et al., 2003, 2004). Fusion is hypothesized 
to be a multi-step process and have several distinct structural intermediates (Figure 1-3). 
Upon first encountering low pH, the E homodimer is thought to dissociate into 
monomers, allowing exposure of the fusion loop and extension of domain II away from 
the viral membrane. The fusion loop, located at the tip of domain II distal from the viral 
membrane, inserts into the target membrane and domain III folds back, allowing for the 
two membranes to be brought in proximity. The alpha helices of the stem region of E 
begin to “zip up” along the E protein domains. As the stem region extends and increases 
its contact with the E protein, hemifusion occurs, in which the outer lipids of each 
membrane mix. This is followed by the final pore formation, which allows for the viral 
genome to be released into the cytoplasm. It is unclear how many E proteins are 
necessary to mediate successful fusion pore formation, and it is possible that the fusion 
pore may “flicker” before opening completely (Harrison, 2008). Supportive mechanistic   
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Figure 1-3. Current model of DENV fusion. (A) DENV envelope protein homodimer in 
its pre-fusion state, resting parallel to the virus membrane. Domains I, II, and III are 
shown in red, yellow, and blue, respectively. Stem region shown in pink. (B) Triggered 
by low pH, the E protein dimer dissociates and the fusion loop, located at the tip of 
domain II, inserts into target membrane. E protein rearranges into trimers. (C) Domain III 
folds back and stem regions begin to zip up the outside of the trimer, bringing membranes 
in proximity. (D) Hemifusion occurs, in which the outer lipid membranes of the virus and 
target membrane mix. (E) Stem region completes zipping up, fusion pore is formed, and 
content mixing occurs between virus and target membrane. Adapted from (Harrison, 
2005) 
A B
C D
E 
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evidence for the extended structural intermediate of Class II fusion proteins has been 
shown in alphaviruses (Sánchez-San Martín et al., 2008), while a study showing that stem 
region peptides interfere with late stages of fusion provide support for interactions of the 
stem region alpha helices with the post-fusion trimer (Schmidt et al., 2010). 
Despite the obvious importance of the DENV E protein in entry, much remains 
unknown about how changes in E structure or sequence influence virus entry or other 
aspects of the viral life cycle. Two studies have suggested that changes in residues around 
the domain I/II interface may alter the optimal pH of viral fusion (Beasley and Aaskov, 
2001; Lee et al., 1997), and this region has been suggested to act as a “hinge” during the 
movement of domain II that occurs during viral fusion (Modis et al., 2003). One recent 
study performed mutagenesis in this region and found that many amino acid changes 
altered either growth kinetics or fusion ability in both mammalian and insect cells 
(Butrapet et al., 2011). Recent work from our lab and others has shown that residues in 
the E DI/DIII linker region (de Wispelaere and Yang, 2012) or stem region (Hsieh et al., 
2010; Lin et al., 2011) can impact virus assembly. These studies suggest that the E 
protein may play a role in steps of the viral life beyond mediating entry. 
 
Inhibition of DENV entry   
  Since the publication of T-20 as a peptide inhibitor of HIV entry (Kilby et al., 
1998), viral entry has been considered a viable target for antivirals. For DENV, the first 
reported instances of inhibitors that acted at entry were peptides loosely derived from the 
stem region of E (Hrobowski et al., 2005). These peptides had an EC50 value of 10-20  
 
 
13 
µM when pre-incubated with virus inocula and present during viral infection, but no 
further exploration into the mechanism of action was explored. 
More recent studies have focused on small molecule, rather than peptide, inhibitors of 
DENV entry (Table 1-1). Many of the studies used high-throughput computational 
screening techniques to identify molecules predicted to bind in the domain I/II interface. 
When the pre-fusion dimer of the DENV2 E protein was crystallized, a single molecule 
of beta-octo-glucoside (BOG), a detergent used in the crystallization buffer, was 
discovered tucked in this region. This area of the E protein was subsequently dubbed the 
“BOG pocket,” and it was hypothesized that a small molecule occupying this same space 
may prevent DENV fusion (Modis et al., 2003). 
  The first antiviral discovered based on high-throughput screening against the 
BOG pocket was published in 2008 (Zhou et al., 2008). The lead compound, P02, 
interacted with the recombinant dengue E protein as detected by NMR and also competed 
with BOG for binding. However, in cellular assays, the compound was tested against a 
yellow fever reporter virus, which, while a flavivirus, has only 44% envelope protein 
sequence similarity to DENV. In addition, P02 was found to be active against a YFV 
replicon that lacks E and other viral structural proteins, suggesting that the compound has 
additional targets downstream of entry that may be responsible for the anti-DENV 
activity observed in cell culture. In fact, the IC50 value against the virus (13 µM) was 
similar to the IC50 against the replicon (17 µM), complicating interpretation of P02’s 
antiviral mechanism(s) of action. 
  A later study explored other potential small molecule inhibitory sites on E and 
identified a compound hypothesized to make contacts with domains II and III that   
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Table 1-1. Previously published inhibitors of DENV entry 
 
Inhibitor name 
Source 
Structure  Activity 
(DENV2) 
Test fusion 
of DENV? 
Activity ag. other 
flaviviruses? 
DN59 peptide 
Hrobowski et 
al, 2005 
 
N/A  
EC50 10 
µM 
No  WNV 
 (EC50 10 µM) 
P02 
Zhou et al, 2008 
 
Not tested  No  YFV  
(EC50 13 µM) 
R1 
Yennamalli et 
al, 2009 
 
EC50 4 
µM 
No  Not tested 
NITD6 
Wang et al, 
2009 
 
EC50 119 
nM 
No  DENV1 (108 nM), 
DENV3 (496 nM), 
DENV4 (334 nM), 
YFV (470 nM),  
JEV (1.42 µM), 
WNV (564 nM) 
A5 
Kampmann et 
al, 2009 
 
IC50 1.2 
µM 
Yes 
(Fusion 
from 
within) 
Kunjin (3.8 µM), 
YFV (1.6 µM) 
 
 
 
 
 
 
 
 
H2N
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Table 1-1, continued. Previously published inhibitors of DENV entry 
 
Inhibitor name 
Source 
Structure  Activity 
(DENV2) 
Test fusion 
of DENV? 
Activity ag. other 
flaviviruses? 
 NITD448 
Poh et al, 2009 
 
 
IC50 9.8 
µM 
Yes 
In vitro 
Not tested 
DV2
419-447 
peptide 
Schmidt et al, 
2010 
 
 
N/A 
IC90 0.3 
µM 
Yes 
In vitro 
(hemifusion 
and pore 
formation) 
DENV1 (0.1 µM), 
DENV3 (2 µM), 
DENV4 (0.7 µM) 
3-110-22 
Schmidt et al, 
2012 
 
IC90 740 
nM 
Yes 
In vitro 
DENV1 (not 
calc.), DENV3 
(not calc.), 
DENV4 (2.3 µM), 
Kunjin (not active) 
  
   
Cl
Cl
O
S
OH
F
F
F
O
O
O OH
O
O
CN
N
H
N CF3 
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lowered DENV yield (IC50 4 µM), although the mechanism of action was not 
investigated (Yennamalli et al., 2009). A highly potent compound, NITD6, was identified 
as a potential ligand of the BOG pocket and shown to associate with dengue virions 
(Wang et al., 2009). NITD6 exhibited an EC50 value of 119 nM in a cell-based 
immunodetection assay and caused the arrest of dengue virions inside endosomes, 
suggesting that inhibition occurred at a late step in viral entry. Other studies have used a 
fusion-from-within assay that measured syncytia formation in insect cells to test whether 
compounds inhibit viral fusion mediated by the E protein (Kampmann et al., 2009). More 
recently, studies have used an in vitro approach to measure DENV fusion in the presence 
of inhibitors using purified virus particles and liposomes as target membranes (Poh et al., 
2009; Schmidt et al., 2012). One study exploring the activity of stem region peptides 
measured both DENV pore formation and hemifusion to determine that the peptides 
inhibited a late step in viral fusion (Schmidt et al., 2010).  
Despite the recent number of publications of DENV entry and fusion inhibitors, 
questions remain. In several cases, the biochemical mechanism(s) by which entry 
inhibition occurs remains to be addressed. In addition, many of the inhibitors have been 
modeled to fit in the BOG pocket of the E protein and make contacts with specific E 
protein amino acids, but high resolution structural data unequivocally establishing the 
BOG pocket as the binding site are lacking. Likewise, no resistance mutations that could 
yield clues to a binding location have been published. Thus, the binding location for all 
molecules remains unclear. 
 
  
 
 
17 
Current work 
  The identification of a spectrum of small molecule and peptide inhibitors of 
DENV entry suggest that entry inhibition may be a viable approach to creating antivirals. 
While currently described DENV entry inhibitors have not yet advanced to preclinical 
development, they have been useful as molecular tools to study mechanisms of DENV 
entry. This study describes our surprising discovery that GNF-2, a small molecule 
inhibitor of intracellular Abl kinases, inhibited DENV when GNF-2 was pre-incubated 
with virus inoculum. Using GNF-2 as a scaffold, we performed an SAR study and 
explored mechanism of action for the identified small molecules. We found that the small 
molecules act post-attachment of virus to cells and block a late step of viral fusion in 
vitro. Through viral passaging against entry inhibitors, we found a single point mutation 
in the DI/II region of the E protein, E(M196V), supporting previous results showing this 
region is important for DENV fusion and consistent with our observation that the 
compounds inhibit this step of DENV entry. The E(M196V) mutation enhanced both 
viral particle production and entry in a single-cycle reporter assay as well as rendered the 
virus particles insensitive to small molecule entry inhibitors. Through a focused alanine 
mutagenesis screen of this region, we identified two other mutations in this region that 
may confer resistance against our small molecules, possibly through enhanced entry as 
well. Overall, this work adds to the growing story of small molecule inhibitors of DENV 
entry and gives support to the earlier hypothesis that the DI/DII interface in the E protein 
is a critical area for viral entry. 
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Chapter 2: Characterization of GNF-2, a small molecule inhibitor of cellular Abl 
kinases, as an inhibitor of dengue virus entry 
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SUMMARY 
  In this chapter, we found that GNF-2, a previously characterized small molecule 
inhibitor of cellular Bcr-Abl kinase, lowers dengue virus (DENV) titer when present at 
two separate times during viral infection. We focused on characterizing the inhibition of 
DENV2 when GNF-2 is pre-incubated with virus inoculum and present only during the 
first hour of target cell infection, an effect that could not be recapitulated with another 
small molecule Abl kinase inhibitor. We found that fluorophore-conjugated GNF-2 co-
localized with DENV2 envelope (E) protein inside cells shortly after infection, and that a 
biotinylated analog of GNF-2 bound directly to purified dengue virions in vitro. Using 
fluorescent polarization assays and recombinant soluble envelope (E) protein, we found 
that a FITC-conjugated GNF-2 derivative interacts with the pre-fusion dimer 
conformation of E. Initially, we used a cell-impermeable analog of GNF-2, c-GNF-2, to 
confirm that inhibition of DENV2 infectivity is independent of intracellular Abl kinases. 
Since c-GNF-2 was over three times less effective at reducing DENV2 infectivity, we 
performed a focused medicinal chemistry study to identify other disubstituted 
pyrimidines with increased potency compared to GNF-2’s activity in the cellular 
infectivity assay. We tested these molecules against other DENV serotypes and found 
that they had wide ranges of activities. Based on the interaction of GNF-2 analogs with 
recombinant E protein and purified virions as well as the range of activities against 
DENV serotypes, we hypothesize that this class of compounds inhibits DENV entry via a 
direct interaction with the DENV envelope protein on the surface of the virion. 
     26 
INTRODUCTION 
  Dengue virus (DENV) is a mosquito-borne virus that causes an estimated annual 
50 million cases of dengue fever worldwide (WHO, 2012). Despite its status as an 
international health concern, much remains unknown about the DENV life cycle. The 
DENV genome encodes only ten viral proteins, making the virus highly dependent on a 
variety of cellular proteins and processes for a successful, productive infection. In an 
attempt to identify cellular kinases that were necessary for successful DENV infection, 
our lab performed a cell-based microscopy screen of small molecule inhibitors that were 
previously published as cellular kinase inhibitors (Chu and Yang, 2007). 
Several small molecules were identified that significantly reduced DENV 
infection. When the kinase selectivities of these compounds were examined, we found six 
of the molecules were known to inhibit the Abl kinase family (Table 2-1). Four of these 
six molecules also have documented activity against Src family kinases (Hennequin et al., 
2006; Holen et al., 1995; Okram et al., 2006; Shah et al., 2004), while one, imatinib, is 
known to inhibit c-Kit, PDGFR, and DDR1/2 (Buchdunger et al., 1996). However, the 
last compound, GNF-2, is an allosteric kinase inhibitor and known to be highly selective, 
exhibiting measurable activity against only Abl family kinases when screened against a 
panel of 450 kinases (Adrian et al., 2006; Zhang et al., 2010). In order to explore the role 
of Abl kinases in DENV infection, we performed additional experiments with imatinib 
and GNF-2, which have similar measured activity against Abl kinases in biochemical and 
cellular assays (Figure 2-1), but work via different molecular mechanisms. Imatinib is an 
active site inhibitor that traps Abl in the ‘DFG-out’ conformation, while GNF-2 is an  
     27 
 
Table 2-1. Small molecule protein kinase inhibitors that inhibit DENV infection, as 
monitored by an immunofluorescence image-based screen. Adapted from (Chu and Yang, 
2007) 
Inhibitor  Src  Abl  c-Kit, PDGFR, VEGFR  Other kinase targets 
K002        CDKs 
K014 (imatinib)    X  X   
K039        c-Raf 
K040        JAK1, -2, -3 
K003  X  X  X   
K013 (GNF-2)    X     
K030  X      Kdr 
K032        CK II 
K117  X       
K045 (AZD0530)  X  X     
K005 (Dasatinib)  X  X  X   
K025 (SU11652)      X  FGFR 
K028 (Lavendustin A)  X      EGFR 
K026 (SU5271)        EGFR 
K144 (Kenpaullone)  X      CDKs, GSK3-b 
K115 (Lavendustin C)  X      CaMK II 
K116 (MC7)        MLCK 
K118 (Tyrphostin46)  X  X  X  Multi-targeted 
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GNF-2, IC50 (kinase) 138 ± 5 nM 
 
 
 
Imatinib, IC50 (kinase) 190 ± 6 nM 
 
 
 
Figure 2-1. Structures of (top) GNF-2 and (bottom) imatinib. IC50 values shown are in 
vitro against Abl family kinases. (Adrian et al., 2006; Buchdunger et al., 1996) 
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allosteric inhibitor of Abl kinase that binds in a hydrophobic myristoyl-binding pocket 
located near the C-terminus of the kinase domain. 
In order to determine when in the viral infectious cycle these compounds exhibit 
anti-DENV activity, we performed order of addition experiments and discovered that 
GNF-2, but not imatinib, inhibited DENV infection when present during two separate 
times during viral infection. While both small molecules inhibited DENV when added to 
cells after initial infection, only GNF-2 lowered DENV yield when pre-incubated with 
virus inoculum. In this chapter, we describe our characterization of GNF-2’s inhibition of 
DENV infectivity when present prior to and during initial cellular infection. We applied 
both cellular and biochemical approaches to explore how GNF-2 inhibits DENV 
infectivity, and collectively our findings led to the hypothesis that GNF-2 interacts with 
DENV envelope protein on the surface of the virion and affects entry. This hypothesis 
was corroborated by our discovery, made in collaboration with the Gray laboratory, of 
GNF-2 analogs that lack Abl kinase inhibitory activity yet have greater potency than 
GNF-2 when present during initial DENV infection. Collectively, these results identified 
GNF-2 and its analogs as inhibitors of DENV infectivity via interactions with the DENV 
E protein and provide chemical tools to investigate mechanism(s) of action in future 
experiments. 
 
RESULTS 
GNF-2 acts at two separate parts of the DENV life cycle 
We initially performed order of addition experiments with GNF-2 and imatinib to 
determine the point(s) in the DENV life cycle during which the small molecules exert   30 
their effect(s). With compounds present at various times during infection (Figure 2-2), we 
infected cells at an MOI of 1 and determined DENV yield by plaque-forming assay 
(PFA) at twenty-four hours post infection, corresponding to approximately one complete 
life cycle of DENV (Lambeth et al., 2005). We found that GNF-2 and imatinib both led 
to a significant reduction in DENV yield when added directly after viral infection, and 
addition of either inhibitor five hours post-infection caused a similar magnitude of 
inhibition (Figure 2-2). The average time between surface binding of virions and 
endosomal fusion for DENV has been shown to be 12.5 minutes (van der Schaar et al., 
2007), strongly suggesting that the small molecules are affecting events downstream of 
viral entry in the DENV life cycle. Our current hypothesis is that this post-entry 
inhibition is due to inhibition of host Abl kinases, since it is observed at a similar 
magnitude with imatinib and GNF-2. Surprisingly, we also observed a significant 
decrease in DENV yield when GNF-2 was pre-incubated with the viral inoculum prior to 
infection. This anti-DENV activity was not observed when the inoculum was pre-
incubated with imatinib, suggesting that it may be due to an Abl-independent mechanism. 
In addition, no reduction in DENV yield was observed when GNF-2 was pre-incubated 
with cells or only present during the one hour initial infection, demonstrating that pre-
incubation of the compound with virus was a critical step for inhibiting DENV. This led 
us to hypothesize that the observed DENV inhibition is due to an interaction of GNF-2 
with a target present in the virus inoculum. 
To further illustrate that GNF-2 inhibits DENV at two separate steps in the viral 
life cycle, one mediated by Abl kinases and one mediated by an independent target, we 
performed additivity experiments with GNF-2, imatinib, and NITD6 (Figure 2-3), a    31 
 
 
Figure 2-2. GNF-2 lowers DENV titer when pre-incubated with virus inoculum. 
Order of addition experiments with GNF-2 and imatinib. Compounds were tested at 15 
µM and BHK-21 cells were infected at a multiplicity of infection (MOI) of 1. DENV 
yield in supernatant was determined by plaque-forming assay at 24 hours post-infection. 
Each bar represents the mean of three replicates with error bars showing standard 
deviation. Student’s t test, * indicates p value < 0.01* 
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NITD6, IC50 198 nM in A549 cells against DENV2 
 
 
 
Figure 2-3. Structure of NITD6, a previously published DENV small molecule entry 
inhibitor (Wang et al., 2009)  
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previously validated inhibitor of DENV entry shown to interact with the DENV envelope 
protein (Wang et al., 2009). EC90 values for each compound were determined in dose-
response titration experiments. GNF-2 and imatinib were both found to have EC90 values 
of 8 µM when added to cells post-infection. When compounds were incubated with virus 
inocula at 37°C for 45 minutes prior to addition to cells, NITD6 had a calculated EC90 
value when present during entry of 200 nM, while GNF-2’s EC90 during entry was 18 
µM. 
Pre-treatment of the virus inoculum with GNF-2 or NITD6 significantly reduced 
DENV titer measured at 24 hours post-infection (Figure 2-4), while post-treatment of 
infected cells with equal molar concentrations of GNF-2 or imatinib also showed 
significant inhibition of DENV yield. Combining pre-treatment of the inoculum with 
NITD6 and post-treatment of cells with imatinib had an additive effect on DENV yield, 
consistent with inhibition of DENV via two separate mechanisms. Importantly, an 
additive effect was also observed when GNF-2 pre-treatment of the inoculum was 
combined with GNF-2 post-infection treatment of DENV-infected cells, showing that 
GNF-2 alone, when present at two separate times during infection, can recapitulate the 
combined effects of NITD6 and imatinib.    
 Together, these data suggest that GNF-2 acts at two separate stages of the DENV 
life cycle: first, blocking DENV entry into cells via a target present in the virus inoculum, 
and second, inhibiting DENV at a post-entry step mediated by a target shared by imatinib 
and GNF-2, presumably Abl kinases. GNF-2’s activity as an intracellular Abl kinase 
inhibitor has been described previously (Adrian et al., 2006), and the role of Abl kinases 
in DENV infection post-entry is currently under investigation by others in our laboratory.    34 
 
 
 
 
Figure 2-4. GNF-2 has additive effects on DENV titer. All virus and cell treatments 
were done at EC90 values determined empirically. Virus treatment was carried out for 45 
minutes at 37°C prior to initial cell infection (MOI 1). Treatment of BHK-21 cells was 
begun immediately after the initial one-hour infection. Each bar represents the mean of 
three replicates with error bars showing standard deviation. * indicates p value < 0.01 
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In this project, we focused on characterizing the previously unknown Abl-independent 
activity of GNF-2 as an inhibitor of DENV infectivity. 
 
A cell impermeable analog of GNF2 retains anti-DENV activity 
In previous studies, GNF-2 has been screened for activity against more than 450 
kinases and found to be a highly selective inhibitor of Abl family kinases (Adrian et al., 
2006). This fact, combined with our result that GNF-2 must be pre-incubated with the 
virus inoculum to cause a significant decrease in DENV yield, led us to the hypothesis 
that GNF-2 acts on an extracellular target present in the virus inoculum. We chose to test 
this hypothesis by using a cell impermeable analog in which the carboxamide 
functionality of GNF-2 was replaced with a carboxylate (c-GNF-2; Figure 2-5). The 
activity of c-GNF-2 against c-Abl kinase in a biochemical kinase assay is comparable to 
that observed with GNF-2 (Choi et al., 2009); however, c-GNF2 was unable to inhibit the 
proliferation of Bcr-Abl transformed Ba/F3 cells  (IC50 > 10 !M versus IC50 140 nM for 
GNF-2), confirming its inability to penetrate the plasma membrane and access the 
intracellular kinase target. In order to assess c-GNF-2’s ability to inhibit DENV infection, 
we pre-incubated the viral inoculum with c-GNF-2 (20-100 !M, 45 minutes, 37 ºC) and 
added the mixture to cells for the initial hour infection, the same conditions used to 
determine the EC90 value during entry of GNF-2. Supernatants were collected at 24 hours 
post-infection and yield of infectious virus present was measured by PFA. Under these 
conditions, we observed a one-log drop in DENV at approximately 60 !M (Figure 2-5), 
showing that c-GNF-2 inhibits DENV infectivity, despite its inability to penetrate the  
   36 
c-GNF-2 
 
 
 
Figure 2-5. c-GNF-2 structure and dose-response titration against DENV2. The 
change to a carboxyl from GNF-2 is circled on the structure. c-GNF-2 was pre-incubated 
with virus inocula for 45 minutes at 37°C before infection of BHK-21 cells (MOI 1). 
Each point represents the mean of three replicates with error bars showing standard 
deviation. EC90 during entry of c-GNF-2 ~60 µM. 
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cellular membrane. This result supports our initial hypothesis that GNF-2 has an 
extracellular target present in the virus inoculum. 
 
CY5-GNF-2 co-localizes with dengue virions after virion uptake 
We hypothesized that GNF-2 may target the virion itself as a way of inhibiting 
DENV infectivity. To examine the location of GNF-2 during viral entry into cells, we 
synthesized a derivative of GNF-2 conjugated to the fluorescent dye CY5. The resulting 
compound, CY5-GNF-2 (Figure 2-6), inhibited DENV in cellular assays with an EC90 
value during entry (~20 !M) similar to that of GNF-2. DENV was incubated with 25 !M 
GNF-2-CY5 before infecting cells (MOI 10) for 30 minutes at 37°C, conditions that were 
empirically determined to permit binding and internalization of virions. Unbound 
compound and virus were removed by extensive washing and cells were fixed to permit 
detection of the DENV envelope (E) protein by immunofluorescence. DENV was visible 
inside cells as punctate staining (Figure 2-7, top row). GNF-2-CY5 was observed inside 
cells when the compound was pre-incubated with DENV inoculum, and the majority of 
this signal co-localized with the E protein (Figure 2-7; middle row). In the absence of 
DENV, little GNF-2-CY5 was observed inside cells (Figure 2-7, bottom row), 
demonstrating the inability of this compound to penetrate the plasma membrane and the 
efficient removal of extracellular compound during wash steps. The uptake of GNF-2-
CY5, moreover, appears to be DENV-specific since it was not observed with a control 
virus, vesicular stomatitis virus (VSV) (Figure 2-8), whose yield was unaffected by pre-
incubation with GNF-2 (data not shown). 
   38 
 
 
GNF-2-CY5 
 
 
Figure 2-6. GNF-2-CY5 structure and dose-response titration against DENV2. GNF-
2-CY5 was pre-incubated with virus inocula for 45 minutes at 37°C before infection of 
BHK-21 cells (MOI 1). EC90 value during entry ~20 µM. Each point represents the mean 
of three replicates with error bars showing standard deviation. 
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Figure 2-7. GNF-2 co-localizes with DENV E protein. DENV was incubated with 20 
µM GNF-2-CY5 prior to infection of cells (MOI 10). Cells were infected for 30 minutes 
at 37°C before fixing and staining for the DENV E protein. (Top row) Cells infected with 
DENV. (Middle row) Cells treated with DENV pre-incubated with GNF-2-CY5. (Bottom 
row) Cells treated with GNF-2-CY5 only. Images are representative of a field of view 
from 2 separate experiments. 
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       VSV G           GNF-2-CY5           Overlay (with DAPI) 
 
 
Figure 2-8. GNF-2-CY5 is not taken up in presence of VSV. Vesicular stomatitis virus 
(VSV) was pre-incubated with 20 µM GNF-2-CY5 at 37°C. Cells were fixed 30 minutes 
post-infection (MOI 10) and stained for VSV G protein. Images are representative of a 
field of view. 
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GNF-2 interacts directly with the dengue virus envelope protein 
  The fact that the anti-DENV effects of both GNF-2 and c-GNF-2 require pre-
incubation with virus inocula prior to infection coupled with the co-localization of GNF-
2-CY5 with DENV E protein inside cells led us to hypothesize that GNF-2 targets the 
dengue virion. To explore this hypothesis, we tested whether a biotin-conjugated 
derivative of GNF-2 (GNF-2-biotin, Figure 2-9) could bind and capture purified DENV2 
virions. GNF-2-biotin was determined to have an EC90 value during entry in cellular 
assays (~18 µM) similar to that of the parental GNF-2.  
Dengue virions were harvested from cell culture supernatant, concentrated by 
PEG precipitation, purified over a potassium tartrate gradient, and dialyzed in TAN 
buffer prior to quantification and incubation with GNF-2-biotin at 37° for 45 minutes. 
Streptavidin beads were used to bind GNF-2-biotin and washed ten times to remove any 
unbound DENV. The beads were boiled in SDS buffer and the released proteins were 
analyzed by Western blot for the DENV E protein. We found that GNF-2-biotin captures 
purified DENV2 virions in a dose-dependent manner (Figure 2-10). 
Knowing that GNF-2 directly interacts with the dengue virion, we next wanted to 
investigate how this interaction between small molecule and virion occurs. The main 
protein component on the dengue virion surface is the envelope (E) protein, which on the 
mature virion associates as a homodimer and tightly packs in a herringbone arrangement 
(Kuhn et al., 2002). It is possible that GNF-2 and conjugated derivatives could bind to the 
virion via non-specific interactions with the lipid bilayer, but we hypothesized that the 
small molecules have a direct interaction with the E protein. To test this, our collaborator 
in Dr. Stephen Harrison’s lab used a fluorescence polarization assay to monitor whether a    42 
 
 
GNF-2-biotin 
 
 
Figure 2-9. GNF-2-biotin structure and dose-response titration against DENV2. = 
GNF-2-biotin was pre-incubated with virus inocula for 45 minutes at 37°C before 
infection of BHK-21 cells (MOI 1). EC90 value during entry ~18 µM. Each point 
represents the mean of three replicates with error bars showing standard deviation.  
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Figure 2-10. GNF-2-biotin interacts with purified DENV2. DENV was precipitated 
and purified over a potassium tartrate gradient before being incubated with GNF-2-biotin 
for 45 minutes at 37°C. GNF-2-biotin concentrations: 10, 5, 1 µM. Streptavidin resin was 
used to bind GNF-2-biotin and washed ten times with HNE buffer to remove any 
unbound virus. Samples were boiled and run on a SDS-PAGE gel and analyzed by 
Western blotting for the DENV E protein using 4G2, an antibody that recognizes the 
fusion loop.  
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FITC-conjugated GNF2 analog (GNF-2-FITC) interacts with a recombinant, soluble form 
of the DENV2 E protein comprised of domains I, II, and III without the stem region, 
which exists as a pre-fusion dimer in aqueous solution (sE dimer). Incubation of GNF-2-
FITC with increasing concentrations of DENV2 sE dimer led to a decrease in 
fluorescence anisotropy (Figure 2-11A), suggesting a physical interaction between GNF-
2-FITC and the pre-fusion DENV2 sE dimer. We also tested whether GNF-2-FITC 
interacted with the DENV2 post-fusion trimer conformation of sE, and found no change 
in fluorescence polarization (Figure 2-11B). These data suggest that the conformation of 
sE affects the affinity of GNF-2-FITC for the protein. 
Taken together, the fluorescence microscopy and in vitro interaction data suggest 
that GNF-2 affects DENV infectivity by binding to the dengue virion, more specifically 
the envelope protein dimer on the virion surface. The envelope protein is responsible for 
all major events of virus entry (binding/attachment, uptake, membrane fusion), making it 
possible that GNF-2 binding could affect any of these events. 
 
GNF-2 has variable inhibitory activity against the DENV serotypes 
Our work up to this point exclusively utilized the DENV2 New Guinea C (NGC) 
strain, so we next asked if GNF-2 could inhibit entry of other DENV serotypes. DENV 
serotypes are defined by differences in the amino acid sequences of the E protein 
(Lindenbach and Rice, 2001), and since we hypothesized that E is the target of GNF-2, 
we reasoned that we might observe variable activity of GNF-2 against other DENV 
serotypes. We performed dose-response titration experiments to determine the effect of 
GNF-2 on the infectivity of strains representative of the other three DENV serotypes.    45 
 
 
Figure 2-11. GNF-2-FITC interacts with recombinant soluble DENV2 E protein 
Fluorescence polarization assay with GNF-2-FITC and soluble recombinant DENV2 E 
protein in (A) pre-fusion dimer or (B) post-fusion trimer conformation. Points represent 
the average of two runs, each in triplicate, with errors bars showing standard deviation. 
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GNF-2 was pre-incubated with virus inocula (MOI 1) for 45 minutes at 37°C, the same 
experimental setup used to determine the EC90 value of GNF-2 and its analogs (Figure 2-
12). DENV1 strain WP74 (EC90 value ~20 !M) and DENV4 strain TVP360 (EC90 value 
~18 !M) exhibited sensitivity to GNF-2 comparable to the previously determined value 
for DENV2 NGC. In contrast, the EC90 value for the DENV3 strain THD3 was greater 
than 40 !M, the highest GNF-2 concentration tested, which only caused a two-fold 
reduction in DENV3 yield. Results with c-GNF-2 showed an even wider range of 
activities. c-GNF-2 had an EC90 value of ~20 !M against DENV4, three times more 
potent than the EC90 value against DENV2. The EC90 value against DENV1 (~60 !M) 
was similar to our previous value against DENV2, while DENV3 THD3 again showed 
only a two-fold decrease in viral yield at the highest c-GNF-2 concentration tested (100 
!M). 
Despite the high level of structural homology among DENV serotypes that is 
evident in high-resolution crystal structures (Modis et al., 2003, 2005), there is only 66% 
conservation of amino acid sequences among the E proteins (Lindenbach and Rice, 
2001). The variable anti-DENV activity of GNF-2 and c-GNF-2 is consistent with our 
observation that the target of GNF-2 is the E protein. 
 
Identification of Abl-inactive GNF-2 analogs that inhibit DENV entry 
  Our work to this point focused on characterizing GNF-2’s inhibition of DENV 
entry, separate from the activity of GNF-2 against intracellular Abl kinases. To do this, 
we used analogs of GNF-2 that were cell-impermeable by virtue of the addition of 
charge, as for c-GNF-2, or conjugation to fluorophores and biotin, as for GNF-2-CY5,    47 
 
 
Figure 2-12. Dose-response titration of GNF-2 and c-GNF-2 against DENV1, 3, and 
4 strains. All DENV strains were diluted to infect BHK-21 cells at an MOI of 1 and pre-
treated with (A) GNF-2 or (B) c-GNF-2 for 45 minutes at 37°C at noted concentrations. 
Each point represents the mean of three replicates with error bars showing standard 
deviation. GNF-2 EC90 values: DENV1 ~20 !M; DENV3 N/A; DENV4 ~18 !M. c-
GNF-2 EC90 values: DENV1 ~60 !M; DENV3 N/A; DENV4 ~20 !M 
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GNF-2-FITC, and GNF-2-biotin. Despite being cell-impermeable and thus unable to 
access intracellular Abl kinases, these latter molecules still inhibited DENV2 infectivity 
with potencies comparable to that of the parental compound, GNF-2, in cellular assays. 
We sought to use medicinal chemistry to more explicitly determine the structure-activity 
relationships governing GNF-2’s effects on Abl kinases versus its effects on DENV 
infectivity. Specifically, we wanted to identify compounds that inhibit DENV entry but 
are devoid of activity against cellular Abl kinases. 
Towards this end, a focused structure-activity relationship study was performed to 
vary the substitution pattern and the substituents on the central pyrimidine core. All 
compounds were designed and synthesized by members of Dr. Nathanael Gray’s lab. A 
total of 112 compounds were initially tested in our pre-incubation assay (37°C, 45 
minutes) at 75 !M; compounds that showed a minimum of a one-log drop in DENV2 
yield were re-tested at 25 !M. Compounds that maintained a one-log drop at this 
concentration were then tested at six concentrations in the pre-incubation assay against all 
four DENV serotypes to obtain an approximate EC90 value (Appendix A). We also tested 
the cytotoxicity of compounds using an ATP proliferation assay (Niles et al., 2007), 
allowing us to calculate an LD90 value. The Gray lab confirmed that all active compounds 
were not able to inhibit the proliferation of Bcr-Abl transformed Ba/F3 cells (IC50 >10 
µM), showing that the compounds are either cell-impermeable or inactive against cellular 
Abl kinases. 
We identified a total of twenty-three disubstituted pyrimidines that inhibited 
DENV2 infectivity with EC90 values equal to or lower than that of GNF-2. Testing these 
compounds against other DENV serotype strains revealed a wide range of activities,   49 
consistent with our hypothesis that E is target of these compounds and mediates their 
effect on DENV infectivity (Appendix A). The DENV3 strain THD3 was insensitive to 
many of the compounds, with no calculable EC90 value for 15 out of the 23 compounds, 
mirroring its lack of sensitivity to GNF-2 and c-GNF-2. On the other end of the spectrum, 
the DENV1 strain had a high level of sensitivity to the presence of many compounds, 
with EC90 values in the single-digit micromolar against 18 out of 23 compounds, and 
EC90 values against the other four compounds were all under 20 µM. The DENV1 results 
are particularly surprising since DENV2 was the focus of our initial SAR study, and we 
only identified nine out of 21 compounds that had single-digit micromolar EC90 values 
against DENV2. Notably, one compound (CVM-7-128-B) was capable of inhibiting all 
four serotypes with EC90 values below 15 µM, suggesting that it may be possible to 
develop pan-serotype inhibitors.  
 
DISCUSSION 
In this chapter, we have identified an unexpected, previously unknown viral target 
for GNF-2, known to be a small molecule inhibitor of intracellular Abl kinases. We found 
that GNF-2 reduces DENV infectivity as measured in yield reduction assays when the 
compound is pre-incubated with virus inoculum. In addition, a combination of 
biochemical, cellular, and chemical experiments collectively indicate that the target of 
GNF-2 is the DENV envelope protein in its pre-fusion form on the virion surface. These 
data do not address how binding of GNF-2 to the DENV E protein leads to a block in 
viral entry; the potential mechanisms of action of GNF-2 and related anti-DENV   50 
compounds generated in our medicinal chemistry study are the focus of the following 
chapter. 
Over the last decade, there has been an increased focus on small molecule and 
peptide inhibitors of viral entry as potential antiviral agents. Entry is considered an 
attractive target for therapeutic intervention since it is an essential step in the viral life 
cycle and occurs early in the viral life cycle before genome replication, thus minimizing 
the chance that the virus may be able to actively evolve an escape mutation. In addition, 
viral entry occurs in distinct, specific steps often involving discrete cellular receptors or 
pathways, thus making it a more tractable target than some downstream steps that often 
use a variety of cellular proteins, not all of them known. However, as demonstrated by 
small molecule HIV entry inhibitors (Araújo et al., 2012; Lu et al., 2012; Westby et al., 
2007) as well as work discussed in Chapter 4 of this dissertation, viruses are still able to 
develop resistance to small molecule or peptide entry inhibitors. 
Virus entry is a multistep process, including initial attachment to cells, uptake into 
cells, and fusion, and there are inhibitors that have been shown to act during all of these 
steps (Baldick et al., 2010; Chen et al., 1997; Kilby et al., 1998; Schmidt et al., 2012). For 
DENV, the E protein on the surface of the virion is responsible for mediating all steps of 
viral entry, and, consistent with our results in the fluorescence polarization assay with 
GNF-2-FITC, has been shown to bind several small molecule or peptide DENV entry 
inhibitors (Schmidt et al., 2012; Schmidt et al., 2010a; Zhou et al., 2008) and 
hypothesized to be the target of several others (Hrobowski et al., 2005; Kampmann et al., 
2009; Poh et al., 2009; Wang et al., 2009; Yennamalli et al., 2009). No experimental 
evidence unequivocally demonstrating the binding site on the E protein binding of GNF-2   51 
or previous DENV entry inhibitors has been reported, although many inhibitors have 
been hypothesized to bind in the interface between domains I and II of E. This region is a 
ligand-binding “pocket” that has been shown to contain a single molecule of beta-octo-
glucoside (BOG) in pre-fusion dimer crystal structures and is hypothesized to be critical 
for conformational rearrangements of E that occur during its mediation of viral fusion 
(Modis et al., 2003). Many DENV entry inhibitors were identified via virtual screening 
against this pocket (Kampmann et al., 2009; Poh et al., 2009; Wang et al., 2009), 
although other studies have identified entry inhibitors by focusing on other regions of the 
E protein (Schmidt et al., 2012; Schmidt et al., 2010a; Yennamalli et al., 2009). Thus, the 
location of binding on E for all DENV entry inhibitors remains an open question. 
Consistent with targeting of the DENV2 E protein by GNF-2, we found that GNF-
2 and its analogs identified in the SAR study had a wide range of activities against other 
DENV serotypes. These results echo previously published DENV entry inhibitors that 
were tested either against other serotypes or flaviviruses. One group showed DENV2-
derived peptides (Schmidt et al., 2010b) as well as small molecule entry inhibitors 
(Schmidt et al., 2012) had a range of activity against other DENV serotypes, but no 
activity against WNV (Kunjin strain). Another study found that a DENV2 entry inhibitor 
(IC50 value 1.2 µM) had activity against WNV (Kunjin strain) as well as YFV 
(Kampmann et al., 2009). The most broadly tested compound published to date, NITD6, 
had measurable activity against all DENV serotypes as well as YFV, WNV, and JEV 
(Wang et al., 2009). However, there were wide variations in potencies; EC50 values 
ranged from 68 nM against DENV2 to 1.42 µM against JEV. It is interesting that several 
studies made note that DENV3 strains were insensitive to both small molecule and   52 
peptide inhibitors of DENV entry; for NITD6, DENV3 had an EC50 value over four times 
higher than against DENV1 or DENV2 (Wang et al., 2009). One group (Schmidt et al., 
2012; Schmidt et al., 2010b) found that DENV3 was less sensitive than other serotypes to 
several peptide and small molecule inhibitors, while modeling done by another group 
(Yennamalli et al., 2009) suggested that the DENV3 envelope protein had lower affinity 
for their small molecule entry inhibitor than even the WNV envelope was predicted to 
have. This mirrors our results with GNF-2 and its analogs, in which we observed a one-
log drop in DENV3 yield with only seven of the twenty-five total molecules tested. 
Further exploration of this pattern of DENV3 insensitivity to entry inhibitors could yield 
information that may help to inform the design of future antivirals targeting the entry step 
or the E protein. 
Although DENV3 was not inhibited by many of our GNF-2 analogs, it was 
sensitive to some. In particular, compound 7-128-B was able to reduce DENV yield by 
one log in all four serotypes at concentrations of 15 µM or less. This result shows that it 
is possible to have pan-serotype small molecule inhibitors of DENV entry. Closer 
examination of the results of our SAR study may provide useful information for the 
design of future entry inhibitors that use GNF-2 as a scaffold and inhibit all DENV 
serotypes with greater potency. 
  GNF-2’s anti-DENV activity during entry is not as potent as most other published 
DENV entry inhibitors, but it is unique among these entry inhibitors due to the fact that it 
also inhibits DENV at a later stage of the viral life cycle, most likely via its inhibition of 
cellular Abl kinases. The unexpected observation that GNF-2 acts at two points in the 
viral life cycle leads to the possible concept of dual-action viral inhibitors. This concept   53 
has been tentatively explored previously in other viruses. One HIV study identified a 
peptide that inhibits glycoprotein gp120 interactions with both of its cell protein ligands 
(Gopi et al., 2006), while another study discovered a small molecule that inhibits two 
separate steps of the HIV integration process (Tsiang et al., 2012). For rhinovirus, an 
inhibitor was identified that prevented activity of two separate viral proteases (Wang et 
al., 1998). However, our results for GNF-2 reveal a molecule that inhibits not at two 
points during one step of the viral life cycle, but rather acts at two separate points in the 
viral life cycle and is likely doing so via two separate targets. This concept is not without 
precedent; a dendrimer was identified with the capacity to inhibit both herpes simplex 
virus (HSV) entry as well as late stages of viral replication (Gong et al., 2002), although 
potential targets were not explored. We propose that it may be possible to use rational 
design to identify molecules that can inhibit viruses via two separate targets at separate 
points in the viral life cycle. The targets could be viral, cellular, or both, as we believe is 
the case for GNF-2. The challenging part of this approach would be to balance 
optimization of inhibitor activity between the two targets. While such dual-action 
inhibitors would be attractive due to their potentially higher barriers to viral resistance, 
this proposition remains to be experimentally explored. 
  In summary, this chapter describes the previously unknown ability of GNF-2 to 
inhibit dengue virus entry in an Abl-independent manner. We used cellular, biochemical, 
and chemical approaches to characterize this activity and determined that GNF-2 most 
likely inhibits DENV entry via interactions with the pre-fusion envelope dimer on the 
virion surface. Our follow-up work in the next two chapters focuses on GNF-2 analogs 
that were identified through a structure-activity relationship study and explores both   54 
potential mechanism of action of the small molecules as well as the question of virus 
resistance to the inhibition of entry. 
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METHODS AND MATERIALS 
Cells and virus: 
BHK-21 cells were maintained in MEM-alpha containing 5% FBS with 5% CO2. C6/36 
were maintained in L-15 media with 10% FBS and no gas exchange. All virus stocks 
were grown in C6/36 cells in L-15 media and 2% FBS, and viral titer was determined by 
plaque- or focus-forming assay in the appropriate cell line (see below). C6/36 cells were 
infected for 1 hour with 3 mL of DENV diluted in EBSS, after which time media was 
added (for a total volume of 20 mL) and the infection proceeded for 4-5 days, until lifting 
of the cellular monolayer was observed. Supernatant was harvested and spun at 1200 rpm 
for 5 minutes to remove cell debris, after which glycerol was added (final concentration 
20%) and samples were aliquoted and frozen at -80°C.  
Order of addition experiments: 
Experiments were carried out in BHK-21 cells using DENV2 NGC in the presence of 15 
!M of GNF-2 or imatinib at times noted in schematic. All virus was diluted in EBSS to 
achieve a multiplicity of infection (MOI) of 1. Cells or virus were pre-incubated in 100 
!L medium containing compounds for one hour at 37°C. For co-infection, 15 !M of 
compound was added to the virus inoculum directly before addition to cells. After an 
initial one hour infection, cells were washed twice with 1X PBS to remove unbound 
compound and virus and 1 mL cell medium (MEM-alpha with 2% FBS) was added. 
Medium was replaced with compound-containing medium at the times noted in 
schematic. Twenty-four hours after initial infection, culture supernatant was collected and 
viral titer was determined by plaque-forming assay.  
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Plaque- and focus-forming assays: 
To determine viral titer, 10
5 cells/well (BHK-21 cells for DENV1, 2, and 4; Vero for 
DENV3) were plated in a 24-well plate and left overnight at 37°C to form a confluent 
monolayer. Ten-fold serial dilutions of the supernatant were made in Earle’s balanced 
salt solution (EBSS) and 100 µL of the dilutions was used to infect each well for one 
hour at 37°C, after which cells were washed once with 1X PBS. Overlay medium was 
added (1.05% CMC with MEM!, 2% FBS, Pen/Strep for BHK-21; 1.05% CMC with 
DMEM, 2% FBS, Pen/Strep for Vero) and plates were incubated for 5 (BHK-21) or 6 
days (Vero). Assays were washed twice with 1X PBS to remove overlay medium and 
cells were fixed. For DENV2, plaque-forming units (pfu/mL) were measured by staining 
the cells with crystal violet and counting the number of plaques. For DENV1, DENV3, 
and DENV4, cells were fixed with 3.7% formaldehyde for 15 minutes at room 
temperature, followed by a 15 minute incubation at RT with 20mM NH4Cl. Cold 60/40 
(vol/vol) MeOH/Acetone was added and plates were kept at -20°C until staining (30 
minutes – overnight). To visualize foci, monolayers were blocked with 1% FBS and 0.1% 
Tween-20 in 1X PBS for 10 minutes at RT and incubated with 1:1000 dilution of mouse 
monoclonal antibody 4G2 for 30 minutes at 37°C. Plates were incubated with horseradish 
peroxidase goat-anti-mouse antibody (1:500) for 30 minutes at 37°C and foci were 
visualized using the Vector VIP substrate kit (Vector Labs, Cat#SK4600). 
EC90 values: 
Compound EC90 values were determined by performing a 6 point titration curve with 
compounds either added immediately after infection and present for the 24 hours of 
infection (imatinib and GNF-2), or pre-incubated with the virus inocula for 45 minutes at   57 
37°C and added to cells for a one hour infection (GNF-2 and all analogs). Cells were 
infected at MOI 1; after 24 hours, supernatants were harvested and PFAs or FFAs were 
performed to determine viral titer. “EC90  of entry” describes compounds that were tested 
by incubating with DENV inocula for 45 minutes at 37°C prior to a one-hour infection of 
cells before being removed along with unbound virus by washing. Viral titers were 
graphed, and the EC90 value was determined to be the point at which a one-log drop in 
titer was observed compared to a DMSO control. EC90 values of entry: NITD6 – 200 nM; 
GNF-2 – 18 !M. EC90 values for cellular treatment: GNF-2 – 8 !M; imatinib – 8 !M. 
Additivity of compounds: 
All compounds were used at EC90 values that were empirically determined (see 
previous). Virus inocula were incubated with compounds in 100 !L for 45 minutes at 
37°C prior to a one-hour infection of BHK-21 cells. After infection, cells were washed 
twice with 1X PBS and 1 mL of fresh medium was added. Twenty-four hours later, 
supernatants were harvested and viral titer was determined by PFA. 
Pull down of DENV: 
Dengue virus was purified from infected C6/36 cell supernatant by incubation overnight 
with PEG8000 to precipitate virus. The virus was pelleted (30 minutes, 9000g), 
resuspended in TAN buffer, placed over a two-step gradient (40% w/v potassium tartrate 
with 30% glycerol, 10% w/v potassium tartrate with 7.5% glycerol), and spun for 2.5 
hours at 35,000 rpm at 4°C. Gradient fractions containing virions (as determined by 
Western blot against the E and C protein) were pooled and potassium tartrate was 
removed by washing with TAN buffer (15 mM TEA,100 mM NaCl, pH 8.0) and 
concentrating the virus in an Amicon filter (Millipore, Cat. # UFC810024). Purified   58 
dengue virions (between 300-400 ng, as measured by Bradford assay) were incubated 
with varying concentrations of GNF-2-biotin for 45 minutes at 37°C in 200 µL HNE 
buffer. Meanwhile, streptavidin resin (GE Biosciences, Cat. #17-5113-01) was rinsed 
twice with HNE buffer, blocked with 5% FBS for one hour at 4°C, and resuspended in 
HNE buffer. Twenty !L of resin was added to the compound and virus and incubated for 
twenty minutes at 4°C. Each sample was washed ten times with 1 mL HNE buffer before 
being resuspended in 20 µL Laemmli sample buffer without beta-mercaptoethanol 
(BioRad, Cat. #161-0737). Samples were boiled (>95°C) for twenty minutes, spun down, 
and run on a 10% SDS-PAGE gel for separation. Proteins were transferred to PVDF 
membrane by semi-dry transfer (10V, 1.5 hrs) and membranes were blotted with 4G2 
antibody for detection of the DENV E protein. Immunoblots were visualized by 
chemiluminescence (Pierce ECL reagent cat#32106). 
Fluorescence microscopy of DENV and CY5-GNF2: 
Vero cells (3x10
4) were plated on coverslips for infection with purified dengue virions 
(0.5 !g) that had been incubated with 25 !M GNF2-Cy5 at 37°C for 1.5 hours. Cells 
were infected for 30 minutes at 37°C, then washed three times with 1X PBS to remove 
any unbound virus or compound and fixed with methanol. Coverslips were stained for the 
DENV E protein (US Biological, Cat. #D2810-05, 1:200) and visualized using FITC-
conjugated goat anti-mouse secondary (Jackson Laboratories Cat. #115-095-146, 1:400). 
Images are at 600X magnification and typical of a broader field of view. 
Fluorescence polarization assay: 
Binding experiments were carried out in Corning, low-volume 384 well microplates and 
analyzed in a PerkinElmer EnVision instrument (excitation wavelength, 485nm; emission   59 
wavelength, 535 nm). Stock concentrations of GNF-2-FITC were made in DMSO and 
dissolved in assay buffer immediately before use. Increasing concentrations of protein 
were used with a constant concentration of compound (25 nM). Each well contained a 
final volume of 20uL in TAN buffer. 
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SUMMARY 
  In earlier work, we discovered that GNF-2, a small molecule inhibitor of cellular 
Abl kinases, inhibited dengue virus (DENV) infectivity via interactions with the envelope 
protein on the virion surface. We performed a focused structure-activity relationship 
study and identified twenty-three small molecule analogs of GNF-2 that had no cellular 
activity against Abl kinases yet inhibited DENV infectivity more potently than GNF-2. 
We chose two of the most potent compounds, 2-12-2 and 8-24-3 (DENV2 EC90 values 
during entry ~5 µM), for further characterization and use in mechanism of action studies. 
We found that the inhibition by these compounds was temperature-dependent, could be 
overcome with higher initial MOIs, and may be reversible. In mechanistic studies we 
found that neither 2-12-2 nor 8-24-3 inhibited attachment of DENV to cells, the first step 
in viral entry. When we measured DENV fusion in vitro, we found that, after treatment 
with the compounds, DENV did not complete the fusion process, although virions still 
stably associated with target membranes in the presence of the compounds. We 
hypothesize that our compounds inhibit DENV entry by interacting with the E protein on 
the surface of the virion in a way that prevents viral fusion with the cellular membrane 
inside endosomes, thus blocking release of the viral genome into the cytoplasm for 
replication. 
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INTRODUCTION 
  Dengue virus (DENV) is a mosquito-borne virus that can cause severe febrile 
disease in humans. Over forty percent of the world’s population is at risk to contract this 
virus, and there are currently no specific treatments or vaccines available (WHO, 2012). 
Dengue is a small, enveloped virion that in its mature, infectious form has one major 
surface protein, the envelope (E) protein, which mediates all steps of viral entry, 
including attachment to cells and fusion between the viral and cellular membranes inside 
endosomes (Harrison, 2005). There are 180 copies of the E protein on the surface of the 
virus, which on the mature virion form 90 homodimers arranged in a tight herringbone 
pattern (Kuhn et al., 2002). E consists of three distinct domains as well as a stem region 
and transmembrane domain; domain I has a !-barrel shape and is centrally located, 
domain II is finger-like in structure and contains the fusion loop at the end distal to the 
viral membrane, and domain III contains the purported receptor binding domain 
(Mukhopadhyay et al., 2005). The stem region consists of two alpha helices that, on the 
mature virion surface, sit underneath the rest of the E protein, close to the viral 
membrane. 
E undergoes a series of conformational changes as it mediates fusion between the 
viral and cellular membranes (Figure 1-3). The pre- and post-fusion structures of E have 
been solved, allowing deduction of the conformational rearrangements that likely occur 
during fusion (Modis et al., 2003, 2004). The initial trigger for these rearrangements is 
the low pH of the endosome, which is thought to initially cause dissociation of the E 
homodimer, allowing extension of domain II and insertion of the fusion loop into the 
cellular membrane. It is thought that domain III then folds back, moving away from   68 
domain II, which forms new contacts with the stem region as the helices move away from 
the viral membrane. Collectively, these structural rearrangements bring the viral and 
cellular membranes in proximity, thereby catalyzing mixing of the outer lipid layers of 
virus and cell to yield a hemifusion intermediate, followed by mixing of the inner lipid 
layer and creation of a fusion pore, allowing release of the viral genome into the cellular 
cytoplasm. 
In earlier work, we discovered that GNF-2, a molecule inhibitor of cellular Abl 
kinases, inhibited DENV infectivity and bound to both purified dengue virions as well as 
recombinant E protein in its pre-fusion, dimer conformation (Chapter 2). We 
hypothesized that GNF-2 inhibits DENV infectivity by interacting with the E protein on 
the virion surface and inhibiting E’s functions in viral entry. As part of this work, we 
conducted a structure-activity relationship study to identify analogs of GNF-2 with 
increased inhibition of DENV infectivity. We identified twenty-three small molecules 
that inhibited DENV2 during entry more potently than GNF-2 yet had no measurable 
inhibition when tested against intracellular Abl kinases (Appendix A).  
This chapter describes efforts to learn more about how select GNF-2 analogs 
inhibit DENV infectivity. To this end, we chose two of the most potent compounds, 2-12-
2 and 8-24-3, from the SAR study (EC90 values ~5 µM) for use in cellular and 
biochemical assays. We examined several parameters, including temperature and time of 
pre-incubation with virus inocula, to gain a better understanding of how the compounds 
interact with dengue virions. In addition, to determine the mechanism by which 
compounds inhibit entry, we examined early and late steps of DENV entry in the 
presence of compounds.    69 
Compounds 2-12-2 and 8-24-3 did not significantly decrease DENV attachment 
to cells, suggesting that they act at a later step of the viral entry process. Using in vitro 
assays, we found that both compounds inhibit a late step in the viral fusion cascade. We 
hypothesize that these compounds interact with the DENV E protein and inhibit DENV 
infectivity by preventing conformational rearrangements necessary for the E protein to 
mediate pore formation, thus preventing release of the genome into the cytoplasm for 
replication. 
 
RESULTS 
Confirmation of GNF-2 analogs as DENV entry inhibitors 
  Our structure-activity relationship (SAR) study using GNF-2 as a scaffold 
identified twenty-three small molecules that significantly lowered DENV2 infectivity at 
concentrations < 25 µM (Appendix A). All compounds were individually tested for 
inhibition of Ba/F3 cell proliferation as a measure of Abl kinase activity and found to be 
inactive (IC50 > 10 µM). We selected two compounds, 2-12-2 and 8-24-3 for further 
experiments to characterize inhibition of DENV infectivity (Figure 3-1). Compound 2-
12-2 had an EC90 value when present during DENV2 entry of ~5 µM and was one of only 
two compounds to inhibit DENV3 yield with a single-digit EC90 value (~5 µM), although 
it was not potent against DENV4 (EC90 value ~40 µM). Compound 8-24-3 was the most 
potent compound against all serotypes other than DENV3 (EC90 values: DENV1, 3 µM; 
DENV2, 5 µM; DENV4, 10 µM). 
In order to confirm that 2-12-2 and 8-24-3 exerted their anti-DENV activity 
during viral entry, we performed order of addition experiments (Figure 3-2). As expected,    70 
      A  2-12-2 
 
 
  B  8-24-3 
 
 
Figure 3-1. Structures of small molecules 2-12-2 and 8-24-3 Small molecules were 
identified in the structure-activity relationship study using GNF-2 as a scaffold. EC90 
values during DENV entry: (A) 2-12-2 – DENV1 4 µM, DENV2 5 µM, DENV3 5 µM, 
DENV4 40 µM; (B) 8-24-3 – DENV1 3 µM, DENV2 5 µM, DENV3 >40 µM, DENV4 
10 µM 
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Figure 3-2. Small molecules lower DENV titer when pre-incubated with virus.  
(A) Cells or (B) virus inocula were pre-incubated with DMSO or 5 µM of compounds for 
45 minutes at 37°C prior to one-hour initial infection (MOI 1). (C) Compounds were 
added to cells at the same time as virus inocula for a one hour infection. (D) Compounds 
were added for one hour after initial infection. Supernatants were harvested 24 hours 
post-infection and DENV yields were determined by plaque-forming assay. Each bar 
represents the mean of three replicates with error bars showing standard deviation.  
* indicates p value < 0.01   
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the compounds did not significantly inhibit DENV when added to cells before, during, or 
after viral infection. A significant drop in DENV yield was observed when compounds 
were pre-incubated with virus inocula, consistent with a viral target. In order to ensure 
that the compounds did not target the cell during the initial hour infection, we also 
performed pre-incubation of the virus with compounds followed by removal of unbound 
compound via gel filtration column. Using this pre-incubated virus inocula to infect cells, 
we observed that DENV infectivity was still significantly reduced, as evidenced by a 
large decrease in the yield of infectious virus produced by 24 hours post-infection; 
moreover, this inhibition was of similar magnitude to the inhibition observed when 
compound was pre-incubated with virus inoculum and then present during the initial 
infection (Figure 3-3). 
As another way to show that the compounds act via a viral target, we performed 
an MOI titration with the compounds. If the target of our compounds is the dengue 
virion, as we hypothesized, we would expect that increasing the amount of virus in the 
initial inocula would overcome the inhibitory effects of the compounds. The EC90 value 
of 5 µM for 2-12-2 and 8-24-3 had been calculated when cells were infected at a 
multiplicity of infection (MOI) of 1, so we retained this compound concentration while 
varying the initial MOI, as measured by plaque-forming units (pfu). Virus and compound 
were pre-incubated for 45 minutes at 37°C and this mixture was added to cells for one 
hour. Cells were washed to remove unbound virus and compound, then medium was 
added and supernatant was harvested 24 hours later to determine DENV titer. We found 
that doubling the amount of infectious virus in the inoculum (MOI of 2) led to a decrease 
in inhibition of DENV infectivity by 2-12-2 and 8-24-3, while by an MOI of 4, no   73 
 
Figure 3-3. DENV titer is reduced when free compound is removed prior to 
infection. (A) DENV was pre-incubated with compound for 45 minutes at 37°C (MOI 1), 
and mixture was added to cells for the initial one-hour infection. (B) DENV was pre-
incubated with compound for 45 minutes at 37°C, and mixture was placed over a 
Sephadex G-50 spin column to remove unbound compound. Flow through was used to 
infect cells for one hour. Supernatants were harvested at 24 hours post-infection, and 
viral yield was determined by plaque-forming assay. Each bar represents the mean of 
three replicates with error bars showing standard deviation. * indicates p value < 0.05 
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difference in DENV yield could be detected between control and compound treated virus 
(Figure 3-4). This result is consistent with our hypothesis that the compounds act via a 
viral target. 
 
Investigating the characteristics of inhibition of DENV entry by compounds 
  After confirming that 2-12-2 and 8-24-3 inhibit DENV when pre-incubated with 
virus inocula and appear to act via a viral target, we wanted to further investigate how the 
compounds inhibited DENV infectivity. We asked if the anti-DENV activity of 2-12-2 
and 8-24-3 was retained when pre-incubation with virus was not done at 37°C. Instead, 
we pre-incubated compound and virus at 4°C, then added the mixture to cells for an 
initial one hour infection at 37°C. We observed no inhibition of DENV infectivity with 
compound treatment under these conditions (Figure 3-5), showing that pre-incubation at 
37°C is necessary for the compounds to exert their anti-DENV activity. We hypothesize 
that thermal motion of the dengue envelope is important in allowing the compounds to 
bind, possibly through transient exposure of binding site(s). 
In all experiments conducted up to this point, compounds 2-12-2 and 8-24-3 had 
been pre-incubated with virus inocula for 45 minutes. Our previous results showed that 
addition of compounds and virus to cells simultaneously did not significantly affect 
DENV infectivity (Figure 3-2), suggesting that some period of pre-incubation is 
necessary for the compound’s anti-DENV activity. We performed a pre-incubation time 
course with 8-24-3 and 2-12-2 in which cells were infected with compound-treated 
DENV after increasing pre-incubation times at 37°C. Unbound compound and virus were 
removed by washing after one hour on cells, and the infection was allowed to proceed for    75 
 
 
 
 
Figure 3-4. Inhibition by compounds is lost with increasing initial MOI. Virus 
inocula (various multiplicities of infection) were pre-incubated with 5 µM 2-12-2 or 8-
24-3 (EC90 values for MOI 1) for 45 minutes at 37°C, and mixture was added to cells for 
the initial one-hour infection. Supernatants were harvested at 24 hours post-infection, and 
viral yield was determined by plaque-forming assay. Each point represents the mean of 
three replicates with error bars showing standard deviation. 
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Figure 3-5. Pre-incubation at 4°C causes loss of inhibition by compounds. DENV2 
(MOI 1) was pre-incubated with 5 µM of compound at either 37°C (left) or 4°C (right) 
for 45 minutes before mixture was added to cells for an initial one hour infection. 
Supernatants were harvested at 24 hours post-infection, and viral yield was determined 
by plaque-forming assay. Each bar represents the mean of three replicates with error bars 
showing standard deviation. * indicates p value < 0.01 
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24 hours, at which point supernatants were harvested and DENV titer was measured. 
With 5 µM 8-24-3, we observed an 80% reduction in DENV infectivity compared to a 
DMSO control after only five minutes pre-incubation, although ten minutes or longer was 
necessary to observe the full one-log drop in DENV titer observed previously with a 45 
minute pre-incubation (Figure 3-6). The anti-DENV activity of 2-12-2 did not occur as 
quickly; a five minute pre-incubation only led to a 45% reduction compared to the 
DMSO control, although this dropped to 80% by 10 minutes, and 45 minutes pre-
incubation was necessary to achieve the full one-log drop in DENV titer. These results 
suggest that binding by 2-12-2 and 8-24-3 to virus may not be instantaneous, but a ten 
minute exposure to virus prior to cellular infection is sufficient to observe a significant 
decrease in DENV infectivity. 
  After learning that our compounds significantly inhibited DENV infectivity 
within ten minutes of pre-incubation, we next asked if we could observe reversion of 
inhibition by 2-12-2 or 8-24-3 when compounds are diluted below active concentrations. 
To test this, we pre-incubated DENV with 20 µM of the compounds in 5 µL for 40 
minutes at 37°C, then diluted the mixture 100-fold to bring compound concentrations to 
200 nM, well below the value at which we can detect anti-viral activity. We used this 
diluted mixture either to immediately infect cells or returned the mixture to 37°C for an 
additional 40 minutes (final MOI 0.4). We found that pre-treatment with 2-12-2 or 8-24-3 
significantly inhibited DENV infectivity when mixture was added to cells immediately 
after the dilution (Figure 3-7). After an additional 40 minute incubation at a higher 
volume, we found no inhibition of DENV infectivity in 2-12-2 treated virus compared to 
our DMSO control, suggesting that the virus inocula recovered from treatment with    78 
 
 
 
 
Figure 3-6. Pre-incubation time with DENV2 affects magnitude of inhibition. 
DENV2 (MOI 1) was incubated with DMSO or 5 µM of compound at 37°C for various 
lengths of time before addition to cells for a one-hour initial infection. Supernatants were 
harvested at 24 hours post-infection, and viral yield was determined by plaque-forming 
assay. Values are expressed as percent of the DMSO control for each time point. Each 
point represents the mean of three replicates with error bars showing standard deviation.  
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Figure 3-7. Inhibition by compounds may be reversible. Five µL DENV was 
incubated with 20 µM compounds for 45 minutes at 37°C, after which it was diluted 
100X fold and either used (A) to immediately infect cells or (B) incubated an additional 
45 minutes at 37°C before being added to cells (final MOI 0.4). Supernatants were 
harvested 24 hours post-infection, and yield was determined by PFA. Each bar represents 
the mean of three replicates with error bars showing standard deviation. * indicates p 
value < 0.05 
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2-12-2. Interestingly, we observed that 8-24-3 treated virus was still significantly 
inhibited relative to the DMSO control even when incubated for 40 minutes at the 
increased volume (Figure 3-7B), although some reversal of inhibition was clearly 
observed when compared to the sample infected with 8-24-3 treated virus immediately 
following dilution (Figure 3-7A). These data, along with the results from the pre-
incubation time course, suggest that the inhibition of DENV infectivity with 2-12-2 and 
8-24-3 is not due to nonspecific inactivation of DENV. The results with 8-24-3 may be 
due to a slower off-rate than that of 2-12-2 from the virus, and a longer post-dilution 
incubation may allow full recovery of DENV infectivity. 
 
Compounds do not block DENV attachment to cells 
Since DENV entry is a multi-step process, we wanted to explore the mechanism 
by which 2-12-2 and 8-24-3 exert their anti-DENV activity. We examined whether the 
first step of viral entry, DENV attachment to cells, was altered in the presence of 2-12-2 
or 8-24-3. Previously, it has been shown that at 4°C, DENV attaches to but is not taken 
up by cells (van der Schaar et al., 2007). Thus, after incubating DENV inocula with 
compounds at 37°C, all subsequent steps were performed at 4°C and washed with chilled 
buffer to prevent cellular uptake of virions. DENV (MOI 1) was incubated for 45 minutes 
at 37°C, moved to 4°C briefly to cool, and then added to chilled cells and rocked gently 
for 2 hours. Cells were washed multiple times to remove unbound compound and virus, 
and either total RNA was extracted from cells immediately or infection was allowed to 
proceed for 24 hours and supernatants were collected. The number of DENV genomes 
bound was determined by qRT-PCR, and we found that treating virus inocula with 2-12-2   81 
or 8-24-3 did not significantly lower the number of viral genomes bound to cells (Figure 
3-8A). When the infection was allowed to proceed, DENV titer was still significantly 
reduced in the compound-treated conditions compared to the DMSO control (Figure 3-
8B). As a positive control, heparin was added to virus inoculum; previous studies show 
that this inhibits DENV entry by preventing binding of virions to cells (Chen et al., 
1997). Taken together, these data show that 2-12-2 and 8-24-3 do not affect attachment of 
DENV to cells and the inhibition by these compounds occurs downstream of initial 
DENV attachment to cells.  
 
Compounds inhibit a late step of DENV fusion in vitro 
We next measured the effect of 2-12-2 and 8-24-3 on the last step of DENV entry, 
the fusion of viral and cellular membranes. DENV fusion with the cellular membrane 
occurs inside endosomes and is hypothesized to be a multi-step process (Figure 1-3), 
making it challenging to dissect specific steps of this biochemical pathway in live cells. 
In order to examine individual steps of DENV fusion, we performed in vitro fusion 
assays in which liposomes are used as a model membrane for fusion with DENV.  
Initially, we examined whether dengue virions formed stable associations with 
target membranes after incubation with 2-12-2 or 8-24-3. This association is a surrogate 
for the fusion loop insertion step in viral fusion (Figure 1-3B) and can be detected in a 
co-flotation assay by determining in which fraction of a sucrose gradient DENV 
equilibrates. At pH 8.0, DENV fusion loops are not exposed and thus virions will not 
form stable association with liposomes; DENV equilibrates near the bottom of the 
gradient. When exposed to pH 5.5, however, fusion loops are exposed and inserted into   82 
 
 
Figure 3-8. Compounds do not block DENV2 attachment to cells. DENV2 was pre-
incubated with DMSO or small molecules at 37°C for 45 minutes before addition to 
chilled cells. Cells were rocked continuously for one hour at 4°C before being washed to 
remove any unbound virus. (A) The number of DENV2 genomes bound to cells 
immediately post-washing, as determined by collecting total RNA and performing qRT- 
PCR with DENV2 primers. (B) Infection was allowed to proceed for 24 hours, and 
DENV yield was determined by plaque-forming assay. Each bar represents the mean of 
three replicates with error bars showing standard deviation. * indicates p value < 0.01 
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target membranes, so DENV equilibrates at a lower density, near the top of the gradient. 
Dengue virions are detected by fractionation of the sucrose gradient, precipitation of 
proteins, and Western blot analysis for the DENV E protein. After control treatment, 
purified DENV equilibrates near the bottom of the gradient at pH 8.0, while at pH 5.5, 
the banding pattern shows a shift in DENV sedimentation (Figure 3-9). Treatment of 
virus with 4G2, an antibody that targets the fusion loops of DENV, caused DENV to 
equilibrate near the bottom of the gradient even at pH 5.5, confirming that DENV 
association with liposomes is mediated by the viral fusion loops. Treatment of DENV 
with 2-12-2 or 8-24-3 revealed the same banding pattern of DENV E in sucrose gradients 
as the DMSO-treated virus, showing that compound treatment of dengue virions does not 
inhibit stable association of virus with target membranes. 
Fusion loop exposure and insertion are early steps in DENV fusion, so we next 
asked if DENV completes fusion in the presence of 2-12-2 and 8-24-3. Formation of a 
fusion pore, the last step in DENV fusion (Figure 1-3E), can be measured via a capsid-
protection assay (Poh et al., 2009; Schmidt et al., 2010). Successful formation of the 
fusion pore between dengue virions and trypsin-loaded liposomes permits trypsin access 
to the contents of the virion, resulting in the degradation of the core (C) protein, an event 
that can be monitored by immunoblotting. The capsid signal is maintained when virus 
and liposomes are incubated at pH 8.0, whereas exposure to pH 5.5 causes a loss of 
capsid signal due to fusion of the virion with the liposome and subsequent digestion of 
the nucleocapsid by trypsin. DENV2 treated with 2-12-2 and 8-24-3 showed retention of 
capsid signal under fusion-promoting conditions (Figure 3-10A and B), while treatment 
of DENV with an inactive control compound, 111-2-B, showed a complete loss of capsid   84 
 
Figure 3-9. Compounds do not inhibit DENV association with target membranes. 
Western blot of coflotation assays with purified DENV2 and liposomes. T=top of 
gradient (lowest density); B=bottom of gradient (highest density) (Top row) At pH 8.0, 
DMSO-treated DENV, as detected by immunoblotting against the E protein, equilibrates 
near the bottom of a sucrose gradient, while exposure to pH 5.5 causes association with 
liposomes and equilibration near the top of the gradient. (Second row) DENV treated 
with 4G2, a mouse antibody targeted at the DENV fusion loop, does not associate with 
liposomes regardless of pH. Antibody against the capsid (C) protein was used to detect 
location of virus in fractions. (Bottom two rows) DENV pre-treated with 2-12-2 or 8-24-3 
shows a pH-dependent sedimentation pattern similar to DMSO-treated virus. 
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Figure 3-10. Compounds prevent completion of viral fusion with target membranes. 
Western blot of capsid protection assay. (A) At pH 8.0, capsid (C) protein can be detected 
via immunoblotting. Exposure to pH 5.5 causes loss of capsid signal in DMSO-treated 
virus, while signal is maintained when virus is pre-treated with 2-12-2 (concentrations: 5, 
15, 25, 40 µM). As a control for trypsin activity, virus and liposomes were treated with 
Triton X-100 (TX100) (B) DENV pre-treated with 8-24-3 (concentrations: 5, 15, 25 µM). 
(C) DENV pre-treated with 111-2-B (concentrations: 10, 20, 40 µM), a compound 
previously shown to be inactive in cellular assays. (D) Repeat of DENV with 2-12-2 
(concentrations: 5, 15, and 25 µM). DENV treated with 4G2, an antibody that recognizes 
the fusion loops, retains capsid signal, showing that capsid digestion is caused by fusion 
mediated by the E protein. 
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signal (Figure 3-10C). This strongly suggests that DENV2 does not complete fusion in 
the presence of 2-12-2 or 8-24-3. To confirm that degradation of the capsid protein is due 
to fusion mediated by the DENV E protein in this assay, we treated DENV with 4G2, an 
antibody that recognizes the viral fusion loops, and found retention of the capsid protein 
at pH 5.5 (Figure 3-10D).  
These data suggest a model in which 2-12-2 and 8-24-3 prevent DENV entry by 
blocking a late step in the viral fusion cascade, thus preventing escape of the DENV 
capsid from the endosome and the delivery of the DENV genome to the cytoplasm for 
replication and productive infection of the host cell. 
 
DISCUSSION 
  In this chapter, we examine the mechanism by which two small molecules, 2-12-2 
and 8-24-3, identified in an SAR study using GNF-2 as a scaffold, inhibit DENV entry. 
In addition to exploring the parameters of compound pre-incubation with virus inocula to 
learn more about how the compounds interact with the virus, we also investigated the 
biochemical mechanism of action of the compounds to determine what step of DENV 
entry they inhibit.  
  Pre-incubation of virus inocula with both 2-12-2 and 8-24-3 had to be carried out 
at 37°C in order to observe DENV inhibition (Figure 3-5), suggesting that the 
compounds’ anti-DENV activity may be dependent on dynamic properties of the DENV 
envelope for transient exposure to binding site(s), either on the E protein itself or the 
virion lipid membrane. Significant inhibition of DENV infectivity by 2-12-2 and 8-24-3 
required a short pre-incubation time with virus inocula (Figure 3-6), as no significant   87 
reduction was observed when virus and compounds were added to cells simultaneously 
(Figure 3-2).  
  We hypothesize that 2-12-2 and 8-24-3 prevent a late step in the viral fusion 
cascade, since compound-treated DENV formed stable associations with liposomes 
(Figure 3-9) but could not complete fusion as measured by formation of the final fusion 
pore (Figure 3-10). The E protein is hypothesized to go through several intermediate, 
transient conformational forms between the pre-fusion dimer and the post-fusion trimer 
that involve movement or rotation of separate domains (Figure 1-3). Our results with 2-
12-2 and 8-24-3 suggest that they block a step after insertion of the fusion loops into the 
target membrane, possibly the fold-back of domain III or association of the stem region 
with the trimer. One way to differentiate between these possibilities would be to examine 
whether hemifusion occurs when DENV is treated with the compounds. An in vitro assay 
measuring hemifusion of pyrene-labeled DENV with liposomes has previously been 
performed to test the activity of inhibitory peptides derived from the stem region of E 
(Schmidt et al., 2010). However, our attempts with this assay did not yield sufficient 
dynamic range to confidently detect hemifusion of DENV. Further optimization of this 
assay may be possible and would allow us to more exactly pinpoint the fusion step 
blocked by 2-12-2 and 8-24-3. Another possible approach to explore DENV fusion more 
precisely would be to test whether recombinant soluble E (sE) protein forms stable post-
fusion trimers after incubation with compounds. 
  Further exploration of the mechanism of inhibition by 2-12-2 and 8-24-3 may 
reveal valuable experimental support for the hypothesized structural fusion intermediates, 
which currently is scarce for flaviviruses. Studies in alphaviruses, which also encode a   88 
class II fusion protein, have confirmed an extended intermediate structure, in which the 
fusion loops are inserted into target membranes, and also revealed that this conformation 
is reversible (Roman-Sosa and Kielian, 2011). However, it is unclear if this is the case in 
DENV, since other studies have shown that domain I/II constructs of the glycoprotein in 
alphaviruses form stable trimers independent of domain III (Sánchez-San Martín et al., 
2008), while DENV domain I/II trimers are not stable until exogenous domain III is 
added (Liao et al., 2010). 
For this study, we chose two of the most potent compounds from the twenty-three 
compounds identified from a SAR study using small molecule GNF-2 as a scaffold. Our 
previous work showed that GNF-2 interacts directly with dengue virions and the DENV 
recombinant sE pre-fusion dimer (Chapter 2). We hypothesize that 2-12-2 and 8-24-3 
also target the E protein but do not have direct experimental evidence to support this. A 
biotinylated derivative of 2-12-2 synthesized by the Gray lab exhibited to a significant 
loss of activity when tested in cellular assays. The order of addition, MOI titration 
experiments, and the fact that the compounds inhibit fusion, a process mediated by E, 
strongly suggest that 2-12-2 and 8-24-3 target the virion or dengue E protein, although it 
is possible, though unlikely, that the compounds interact non-specifically with the lipid 
envelope of the virus. In addition, the location of binding on the E protein remains 
unknown for GNF-2, 2-12-2, and 8-24-3; even if the latter compounds interact with E, 
the binding sites may differ. Another open question is whether GNF-2, as well as other, 
untested compounds from the SAR study, block the same step of DENV entry as 2-12-2 
and 8-24-3. Testing GNF-2 and the other analogs in the cellular and biochemical assays 
presented in this chapter would address this question.   89 
One potential binding location on the E protein for GNF-2, 2-12-2, and 8-24-3 is 
the “hinge region” located between domains I and II. This site has previously been shown 
to be a ligand binding site, as crystallization of recombinant E revealed a single molecule 
of beta-octo-glucoside (BOG) in the pocket formed by domains I and II (Modis et al., 
2003). Several other small molecule inhibitors of DENV entry have also been 
hypothesized to bind in this area (Poh et al., 2009; Schmidt et al., 2012; Wang et al., 
2009). However, binding in this region was originally predicted to inhibit the extension 
of domain II of E away from the viral membrane and hence block the insertion of the 
fusion loops into a target membrane (Modis et al., 2003). Our experiments show that 
DENV treated with 2-12-2 or 8-24-3 makes stable associations with lipid bilayers, 
suggesting the block by these compounds occurs later in the fusion cascade. It is possible 
that binding in the domain I/II interface does not prevent fusion loop exposure, or the 
compounds may bind in a different location on the E protein. A previous study identified 
two other regions of the E protein that were predicted to be potential small molecule 
binding locations that prevent conformational changes of E that occur after insertion of 
the fusion (Yennamalli et al., 2009), so it is possible that our compounds could bind in 
either of these additional locations. 
Overall, this chapter characterizes inhibition of DENV infectivity by two Abl-
inactive small molecules that were identified in our SAR study. Using both cellular and 
biochemical assays, we have discovered that inhibition by 2-12-2 and 8-24-3 is 
temperature-dependent and lost when initial DENV MOI is increased. Neither compound 
blocked attachment of the virus to cells or prevented viral association with membranes, 
although they did prevent viral fusion pore formation with target membranes. Further   90 
exploration of how these compounds inhibit DENV fusion may reveal valuable 
information about conformational intermediates of the E protein as it mediates viral 
fusion.     91 
METHODS AND MATERIALS 
Order of addition experiments 
DENV2 (NGC strain) was used to infect BHK-21 cells in 24-well plates at an MOI of 1 
for all experiments. Compounds were used at 5 µM. Cells or virus were pre-incubated in 
100 µL medium containing compounds or DMSO at 37°C (cells: 1 hour; virus: 45 
minutes) or 4°C (pre-incubation temperature; Figure 3-5). For co-infection, 5 !M of 
either compound or DMSO was added to virus inoculum directly before addition to cells. 
After an initial one hour infection, cells were washed twice with 1X PBS to remove 
unbound compound and virus and 1 mL cell medium (MEM-alpha with 2% FBS) was 
added. For post-treatment of cells, compound was added to medium for 1 hour post-
infection, then removed and cells were washed twice and medium was replaced. Twenty-
four hours after initial infection, supernatant was collected and viral titer was determined 
by plaque-forming assay.  
Removal of unbound compounds by gel filtration column 
DENV2 (NGC strain) inocula (MOI 2) was pre-incubated in 100 !L with 10 !M of 
compound or DMSO for 45 minutes at 37°C, then placed over a Sephadex G50 spin 
column and spun for 2 minutes at 2000 rpm at room temperature. Eluant was used to 
infect cells for 1 hour, after which cells were washed twice with 1X PBS to remove 
unbound compound and virus, and 1 mL cell medium (MEM-alpha with 2% FBS) was 
added. Twenty-four hours after initial infection, supernatant was collected, and viral titer 
was determined by plaque-forming assay.  
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Multiplicity of infection (MOI) titration  
DENV2 (NGC strain) inocula (various MOI) were pre-incubated with 5 !M of 
compound or DMSO for 45 minutes at 37°C. After an initial one hour infection, cells 
were washed twice with 1X PBS to remove unbound compound and virus, and 1 mL cell 
medium (MEM-alpha with 2% FBS) was added. Twenty-four hours after initial infection, 
supernatant was collected, and viral titer was determined by plaque-forming assay. 
Pre-incubation timecourse 
DENV2 (NGC strain) inocula (MOI 1) was pre-incubated with 5 !M of either compound 
or DMSO for noted time at 37°C. Mixture was added to cells and left at 37°C for exactly 
one hour with gentle rocking. After the one hour infection, cells were washed twice with 
1X PBS to remove unbound compound and virus, and 1 mL cell medium (MEM-alpha 
with 2% FBS) was added. Twenty-four hours after initial infection, supernatant was 
collected, and viral titer was determined by plaque-forming assay. 
Reversibility experiments 
Due to the initial small volume of the virus, experiments were performed to determine the 
correct concentration of compounds to use in order to observe a consistent one-log drop 
in DENV titer. Five DENV !L (10
7 pfu/ml) was incubated with 20 !M of 2-12-2 or 8-
24-3 or DMSO for 40 minutes at 37°C. Virus was diluted 100X and 200 !L was used to 
infect BHK cells (effective MOI: 0.4) immediately or after an additional 40 minute 
incubation at 37°C. One hour after virus mixture was added to cells, cells were washed 
twice with 1X PBS to remove unbound compound and virus, and 1 mL cell medium 
(MEM-alpha with 2% FBS) was added. Twenty-four hours after initial infection,   93 
supernatant was collected, and viral titer was determined by plaque-forming assay. 
Plaque-forming assays  
To determine viral titer, 10
5 BHK-21 cells/well were plated in a 24-well plate to form a 
confluent monolayer. Ten-fold serial dilutions of culture supernatant were made in 
Earle’s balanced salt solution (EBSS), and 100 µL of the dilutions were used to infect 
cells for one hour at 37°C with gentle rocking, after which cells were washed once with 
1X PBS. Overlay medium was added (1.05% CMC with MEM", 2% FBS, Pen/Strep) 
and plates were incubated for 5 days (BHK-21). Assays were washed twice with 1X PBS 
to remove overlay medium, and cells were fixed with a mixture of 0.5% crystal violet and 
3.7% formaldehyde. After a minimum of four hours, plates were washed, and plaques 
were counted.  
DENV binding to cells 
DENV2 (NGC strain) was incubated with either 5 !M of 2-12-2 or 8-24-3, 20 !g/ml of 
heparin, or DMSO for 45 minutes at 37°C, then added to BHK cells (MOI 1) at 4°C for 
one hour with constant rocking. Cells were washed three times with cold 1X PBS to 
remove unbound virus or compound. For quantitation of viral genomes bound, total RNA 
was extracted using Trizol according to manufacturer’s instructions. For viral yield 
determination, one mL of medium was added (MEM-alpha with 2% FBS), and culture 
supernatant was harvested 24 hours later. RT-qPCR was performed to determine number 
of DENV genomes present using primers against the C protein region of the genome. To 
determine viral titer in supernatant, plaque-forming assays were performed. 
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Quantification of DENV genomes 
Quantification of DENV genomes was done on a MyIQ Cycler (Biorad). After RNA 
extraction and quantification, 5 !L of RNA was used to make cDNA with the iScript kit 
(Biorad) according to manufacturer’s instructions. The resulting cDNA was digested by 
RNaseH for 1 hour at 37°C. Quantification by rt-PCR was done on each sample in 
triplicate (25 !L each) using SybrGreen Supermix (Biorad) according to manufacturer’s 
instructions. Primers used targeted the DENV C gene.  
DV2Cfor  5’-AATATGCTGAAACGCGAGAGA-3’  
DV2Crev  5’-GGGATTGTTAGGAAACGAAGG-3’ 
Liposomes 
Liposomes were made with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) (Avanti Polar Lipids 
cat # 850457 and 850757, respectively), and cholesterol (Sigma-Aldrich cat#C3045) at 
1:1:2 molar ratio in TAN buffer (20mM triethanolamine, 100mM NaCl, pH 8.0). Lipids 
were dried down and resuspended thoroughly by vortexing and sonication. Liposomes 
were prepared by extrusion through a 0.2 micron filter after five freeze/thaw cycles. For 
trypsin-containing liposomes, 10 mg of trypsin was added to 1 mL of lipids (3 mg each) 
after the third freeze/thaw cycle, prior to extrusion. Liposomes were separated from 
unincorporated trypsin by size-exclusion chromatography using a Superdex 200 column 
on an Akta fast performance liquid chromatography (FPLC) system. Trypsin-containing 
liposomes were used within 24 hours; liposomes for coflotation were used within three 
days. 
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Coflotation assay 
Purified dengue 2 virus (600 ng as quantified by Bradford assay) was incubated with 40 
!M of compounds or DMSO for 45 minutes at 37°C in 200 !L TAN buffer (pH 8.0). 
Liposomes (20 !L) were added for ten minutes, followed by lowering of the pH by 
addition of 15 !L 1M sodium acetate (pH 5.0). Following a ten minute incubation, 
samples were back-neutralized with 30 !L 1M TEA (unbuffered). Samples were then 
mixed with 25% sucrose in TAN buffer (pH 8.0) and placed into a four step gradient 
(60%, 25%, 15%, 5% sucrose in TAN buffer) and spun for 3 hours at 44,000 rpm. 
Gradients were fractionated and 20% TCA (total volume) was added to precipitate 
proteins. Samples were washed twice with 1 mL acetone, and sample buffer was added. 
Fractions were boiled for 20 minutes and run on a 10% SDS-PAGE gel followed by 
semi-dry transfer to a nitrocellulose membrane. 4G2 antibody, grown in house from 
ATCC cell line HB-112, was used for detection of DENV envelope (dilution varies by 
lot), and the neat supernatant of hybridoma cell line 6F3.1, kindly provided by Dr. John 
Aaskov, was used to detect capsid protein. 
Capsid protection assay 
Purified dengue 2 virus (300 ng) was incubated with various concentrations of 
compounds (5-40 !M) for 45 minutes at 37°C in TAN buffer (pH 8.0) prior to addition of 
liposomes (7.5 !L of peak fraction from column) for ten minutes. After incubation with 
liposomes, 7.5 !L 1M sodium acetate (pH 5.0) was added to drop pH to 5.5 for ten 
minutes. Samples were back-neutralized with 15 !L 1M TEA (unbuffered) and incubated 
for forty-five minutes at 37°C to allow trypsin digestion (total volume: 100 !L). SDS 
sample buffer (20 !L) was added, and samples were boiled for 20 minutes before being   96 
run on a 12% SDS-PAGE gel to separate proteins. Proteins were transferred to a 
nitrocellulose membrane using a semi-dry transfer. 4G2 antibody, grown in house from 
ATCC cell line HB-112, was used for detection of DENV envelope (dilution varies by 
lot), and the neat supernatant of hybridoma cell line 6F3.1, kindly provided by Dr. John 
Aaskov, was used to detect capsid protein. 
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SUMMARY 
  In this chapter, we examined the effect(s) of amino acid changes in the DENV 
structural proteins on susceptibility of the virus to small molecule entry inhibitors. We 
serially passaged DENV2 in the presence of select compounds and tracked viral titer to 
monitor the emergence of inhibitor-resistant DENV. This approach yielded a rise in titer 
against one out of ten tested compounds, 7-148-6. Sequencing of the structural proteins 
from this virus revealed two changes: one each in the E protein, E(M196V) and M 
protein, M(H28Y). Testing of these individual residues in a single-cycle infection assay 
using recombinant viral particles (RVPs) (Wang et al., 2009a) revealed that E(M196V) 
enhanced entry of virus particles, while M(H28Y) decreased the efficiency of entry. 
RVPs containing either change showed no significant decrease in reporter signal when 
pretreated with 7-148-6. E(M196V) is located in a “hinge” region between domains I and 
II of the E protein that has been hypothesized to be critical for conformational 
rearrangements necessary to mediate membrane fusion (Modis et al., 2003). Using the 
RVP system, we performed site-directed mutagenesis of eleven selected residues in this 
region and found that eight mutations decreased production or impaired entry of RVPs. 
We focused on two mutations, E(Q52A) and E(Q131A), and found that they conferred 
resistance against three small molecule entry inhibitors. Overall, our data suggest changes 
in the E protein domain I/II interface may confer resistance to small molecule entry 
inhibitors and affect production or release of viral particles as well as their entry into 
target cells. 
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INTRODUCTION  
  Dengue virus (DENV) is one of the most common vector-borne viruses in the 
world, causing an estimated 50 to 100 million illnesses per year (WHO, 2012). There are 
no specific therapeutics or vaccines available against DENV, making antivirals to treat 
the disease highly desirable. Virus entry is considered an attractive antiviral target in part 
because blocking entry can prevent primary infection or viral spread. For DENV, virus 
entry is mediated by the envelope (E) protein, the major glycoprotein on the virion 
surface. 
  DENV E consists of three domains (Figure 4-1) and mediates binding to cells as 
well as fusion with the cellular membrane, which is triggered by low pH inside 
endosomes after DENV is endocytosed (Gollins and Porterfield, 1986). Domain I is 
centrally located, while finger-like domain III extends along the virion surface and 
contains the fusion loop at its distal end, and domain III has an immunoglobulin-like fold 
that contains the purported receptor-binding region (Mukhopadhyay et al., 2005). When 
the E protein is first synthesized into the ER lumen, it associates with prM, a protein that 
acts as a chaperone for E, and forms a heterodimer. This E/prM heterodimer is found on 
the surface of newly-assembled virions in the endoplasmic reticulum as trimeric spikes 
(Zhang et al., 2003b). As virions pass through the trans-Golgi network, E reassociates 
into homodimers, and the pr peptide is cleaved by furin, leaving the small M protein 
resting underneath the E dimers on the now-mature virion surface (Zhang et al., 2003a). 
It is hypothesized that the domain I/II interface of E acts as a hinge region during 
viral fusion, allowing extension of the fusion loop towards the cellular lipid membrane 
(Modis et al., 2004).  The region between domains I and II of the E protein is often    103 
 
 
 
 
 
Figure 4-1. Crystal structure of the DENV2 envelope protein. DENV2 envelope (E) 
protein as a homodimer, the pre-fusion form found on the surface of mature virions. 
Domains I, II, and III of one E monomer are shown in red, yellow and blue, respectively. 
PDB ID: 1OAN (Modis et al., 2003)   104 
referred to as the “BOG” pocket, as it was discovered to contain a single molecule of 
beta-octo-glucoside (BOG) under certain crystallization conditions (Modis et al., 2003). 
In high-resolution crystal structures, the pocket adopts a closed conformation with the k-l 
loop covering an opening between the domains when BOG is present but exhibits an 
open pocket due to shifting of the k-l loop when BOG is absent. Based on this 
observation and previous studies indicating that residues lining this region may alter the 
pH threshold of fusion (Beasley and Aaskov, 2001; Lee et al., 1997), it was proposed that 
the presence of a small molecule ligand in the BOG pocket may interfere with DENV 
entry by preventing the structural rearrangements involved in DENV fusion. An attractive 
feature of this proposal is that any mutations in this region that could confer resistance 
would be expected to decrease the fitness of the virus due to their potential effect(s) on 
fusion.  
Since this potential strategy for inhibiting DENV was proposed, several inhibitors 
of DENV entry hypothesized to bind in the BOG pocket have been reported (Kampmann 
et al., 2009; Poh et al., 2009; Schmidt et al., 2012; Wang et al., 2009b); however, 
structural data directly demonstrating this has yet to be published. Likewise, genetic data 
mapping resistance mutations to this or any other region of the E protein have not been 
reported, although whether this is due to the effect of such mutations on E’s function and 
the fitness of the corresponding virus remains unclear. 
Previously, we identified several small molecules that inhibited DENV when pre-
incubated with virus inocula prior to initial infection of cells. We hypothesized that these 
compounds act on a viral target, specifically the envelope protein on the surface of 
virions, and showed that select compounds inhibited DENV fusion in vitro. In this study,   105 
we report efforts to learn more about the molecular interactions of these inhibitors with 
the dengue virion by using mutational analysis to explore the molecular target of the 
inhibitors and potential mechanisms of resistance to these inhibitors. We serially 
passaged DENV2 in the presence of ten select compounds and monitored for outgrowth 
of DENV that would suggest viral resistance. We observed outgrowth of DENV in only 
one out of ten compound treatments, with small molecule 7-148-6. Consensus sequencing 
of the structural proteins of this resistant quasispecies led us to the identification of two 
point mutations, one in the domain I/II of the E protein, E(M196V), and one in the 
ectodomain of M, M(H28Y). We found that in a single-cycle DENV reporter assay, the 
presence of either mutation was sufficient to confer insensitivity to treatment of virus 
particles with 7-148-6. In parallel, we performed a rational, site-directed mutagenesis 
study of eleven residues around the domain I/II interface of E. We found that eight of 
these changes drastically reduced virus particle production or entry. We tested two amino 
acid mutations that were still permissive for efficient RVP entry, Q52A and Q131A, 
against select small molecule entry inhibitors GNF-2, 2-12-2, and 7-148-6, and found 
both the presence of either mutation reduced sensitivity to treatment relative to wild-type 
RVPs. Taken together, our data suggest that the DI/DII interface is sensitive to many 
amino acid changes; however, changes that are tolerated may decrease sensitivity to the 
small molecule entry inhibitors examined in these experiments. The results presented 
here aid in understanding the interaction of our small molecule inhibitors with the DENV 
E protein and also suggest that point mutations at the interface of domains I and II of E 
affect viral particle production and entry. 
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RESULTS 
Potential resistance of DENV2 to presence of small molecule 7-148-6 
  To examine the potential development of resistance to a subset of our small 
molecule entry inhibitors, we serially passaged virus in the presence of compounds using 
two approaches. We first tried passaging DENV2 in the presence of 20 µM of four small 
molecules (7-128-B, 7-148-1, 7-148-6, and 7-148-8) previously shown to inhibit DENV 
infection yet inactive against intracellular Abl kinases (Appendix A). Over the course of 
eight passages, we saw a rise in viral titer suggestive of a resistant virus strain against 
only one of the compounds, 7-148-6 (Figure 4-2). Concerned that the high initial 
concentration of compounds had prevented outgrowth of resistant DENV, we selected 
another six compounds, 1-100-1, 2-12-2, 2-21-2, 8-24-3, 8-24-5, and 2-119-2-B, for a 
second serial passage. We gradually increased compound concentrations from 2.5 to 20 
µM over the course of nine passages, but found that viral titers crashed as the EC90 values 
of compounds were reached and did not recover (data not shown). Thus, out of ten 
compounds tested, we identified viral outgrowth against only one, suggesting that DENV 
may not easily develop resistance to the small molecule entry inhibitors. 
We turned our attention to compound 7-148-6 (Figure 4-3) and confirmed that it 
mirrored the activity of our previously tested compounds, 2-12-2 and 8-24-3, in the order 
of addition experiments and that it exhibited anti-DENV activity even after size-
exclusion chromatography was used to remove unbound compound from the inoculum 
prior to infection of cells (Figure 4-4). We tested 7-148-6 in biochemical mechanism 
assays and found that it does not inhibit attachment of DENV to cells but does block 
completion of DENV fusion in vitro (Figure 4-5). We hypothesize that 7-148-6 inhibits    107 
 
 
 
 
 
 
Figure 4-2. Passaging of DENV2 in the presence of selected compounds. DENV2 was 
passaged every four days in Vero cells in the presence of DMSO or 20 µM of each 
compound. DENV titer was determined by plaque-forming assay. Each point represents 
the mean of three replicates with error bars showing standard deviation. 
 
   
0 2 4 6 8
100
101
102
103
104
105
106
107
Passage number
v
i
r
a
l
 
t
i
t
e
r
 
(
p
f
u
/
m
l
)
DMSO
7-128-B
7-148-1
7-148-6
7-148-8  108 
 
 
 
 
 
 
Figure 4-3. Structure of compound 7-148-6. EC90 values against DENV serotypes in 
infectivity assay: DENV1 – 8 µM; DENV2 – 10 µM; DENV3 >40 µM; DENV4 >40 µM. 
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Figure 4-4. Compound 7-148-6 inhibits DENV titer when pre-incubated with virus 
inoculum. (A) Order of addition experiments show a significant reduction in viral yield 
only when compound 7-148-6 (10 µM) is pre-incubated with DENV2 inoculum at 37°C. 
(B) Significant inhibition of DENV infectivity by 7-148-6 is observed when free 
compound was removed via a gel filtration spin column prior to cellular infection. Each 
bar represents the mean of three replicates with error bars showing standard deviation.  
* indicates p value < 0.01 
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Figure 4-5. Compound 7-148-6 does not affect virus attachment to cells and prevents 
completion of DENV fusion. DENV was incubated with 7-148-6 (10 µM), DMSO, or 
heparin sulfate (20 µg/ml) for 45 minutes at 37°C, after which mixture was added to 
chilled cells for 1 hour at 4°C. After washing, (A) total RNA was extracted for qRT-PCR 
or (B) infection was allowed to proceed for 24 hours and viral yield was measured by 
PFA. Each bar represents the mean of three replicates with error bars showing standard 
deviation. * indicates p value < 0.01 (C) Western blot against the DENV E and C proteins 
shows retention of the C signal when purified DENV is treated with 7-148-6 (10, 20, 30, 
40 µM) prior to exposure to pH 5.5 in the presence of trypsin-containing liposomes. 
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DENV entry by blocking a late step in DENV fusion via interactions with the E protein 
on the virion surface. These results confirm that 7-148-6 behaves similarly to our other 
tested compounds, 2-12-2 and 8-24-3 (Chapter 3), and can be used as a tool to explore 
DENV resistance against the small molecule entry inhibitors. 
 
Sequencing of resistant virus reveals two changes in the DENV structural proteins 
  In order to identify what sequence change(s) caused the observed rise in DENV2 
titer, we extracted viral RNA from passage 6 of the 7-148-6 passaged virus (Figure 4-2). 
Consensus sequencing of the viral structural proteins C, prM, and E revealed a single 
amino acid change in the DENV2 envelope protein at position 196, from methionine to 
valine (Figure 4-6). This E(M196V) change was not observed in DENV2 that had been 
passaged in the presence of DMSO. Residue 196 is located at the base of the BOG pocket 
located between domains I and II, a region of the protein that has been hypothesized to 
act as a hinge during the conformational changes that occur during viral fusion (Modis et 
al., 2003), consistent with our hypothesis that the anti-DENV activity of 7-148-6 is due to 
inhibition of DENV fusion. The methionine at this position is conserved across all four 
DENV serotypes although it is not present in more distantly related flaviviruses such as 
West Nile or Japanese encephalitis virus.  
  Our consensus sequencing, while identifying E(M196V), also revealed that this 
change was incomplete. This raised the possibility that consensus sequencing may have 
obscured other changes in the structural genes, so we performed a single round of virus 
plaque isolation, expansion, and sequencing. This viral sequencing led to the 
identification of an additional amino acid change, present in 6/7 plaques of the 7-148-6    112 
 
 
Figure 4-6. Location of residue 196 on DENV2 E protein. Pre-fusion envelope dimer 
crystal structure (Modis et al., 2003). Magnification is of the domain I (red) – domain II 
(yellow) interface. (Inset) The methionine at position 196 is highlighted in green. In 
DENV2 serially passaged in the presence of 20 µM of 7-148-6, consensus sequencing 
revealed a valine at this position. 
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passaged virus and 0/3 of virus plaques passaged in the presence of DMSO. This change 
was a histidine to tyrosine mutation located at residue 28 in the ectodomain of the M 
protein. The M protein is the post-cleavage remnant of the chaperone protein prM, and no 
functional role has yet been described for M in the viral entry process. A study that used 
electron density to map the location of M on the surface of the mature dengue virion 
suggests that the ectodomain takes the form of two alpha helices, one of which is 
amphipathic and makes contact with the lipid bilayer of the virion and possibly the 
underside of the E protein as well (Kuhn et al., 2002); M(H28Y) is hypothesized to be 
located in this helix. 
   
Effect of structural protein mutations on production and entry of single-cycle 
reporter virus 
To investigate the potential of each identified amino acid change to confer 
resistance, we used a reporter virus particle (RVP) system (Ansarah-Sobrinho et al., 
2008). The RVP system uses two plasmids to produce single-cycle infectious viral 
particles, with luciferase signal as the readout of a successful infection. One plasmid 
encodes for DENV structural proteins C, prM, and E, while the second encodes a West 
Nile virus (WNV) genome in which structural proteins have been replaced with the 
Renilla luciferase gene. Transfection of cells with both plasmids allows for the 
production of recombinant virus particles (RVPs) comprised of the DENV structural 
proteins and containing a WNV RNA genome. Entry of RVPs is mediated by the DENV 
E protein on the particle surface and is thought to occur via the same mechanisms as 
authentic DENV. Following entry, the WNV RNA is translated and replicated, and   114 
quantification of the resulting luciferase activity provides a measure of the steady-state 
abundance of WNV RNA. Accordingly, to examine the effects of the E(M196V) and 
M(H28Y) mutations on RVP production and entry, we engineered each mutation into the 
plasmid encoding the DENV2 CprME genes and used these plasmids to produce RVPs. 
We initially determined the effect of E(M196V) or M(H28Y) on RVP production 
by quantifying the number of WNV replicons present in producer cell supernatant by 
qRT-PCR (Figure 4-7A). No significant difference in genome copy number was detected 
for either mutation when compared to wild-type RVP production. It is important to note 
that quantification of WNV genomes measures the release of recombinant viral particles 
that encapsidate RNA, but does not measure any potential differences in empty particle 
release. Unfortunately, due to the low number of RVPs in the supernatant, our attempts to 
detect any changes in the release of E protein or empty particles by transfected cells were 
unsuccessful. 
We next asked if E(M196V) or M(H28Y) affected entry of RVPs into target cells. 
Wild-type, E(M196V), or M(H28Y) RVPs were diluted to normalize for WNV genome 
copy number and added to target cells for a one hour initial infection. Cells were washed 
to remove unbound RVPs and fresh medium was added. Sixteen hours after infection, 
cells were lysed, and luciferase activity was determined. We observed that E(M196V) 
RVPs had a significant increase in luciferase signal compared to wild-type RVP signal, 
while M(H28Y) RVPs had a significant decrease (Figure 4-7B). These data show that 
both mutations impact entry of viral particles, although in different directions.  
 
     115 
 
Figure 4-7. DENV structural protein mutations affect virus entry in a single-cycle 
infection assay. Recombinant viral particles (RVPs) containing either E(M196V) or 
H(28Y) were produced by transfection of 293T cells with two plasmids: one encoding the 
WNV luciferase reporter replicon and one encoding the DENV structural cassette.  
(A) RVPs in producer cell supernatant were quantified by performing qRT-PCR against 
the WNV replicon. Each bar represents the mean of three replicates with error bars 
showing standard deviation. (B) After quantification, RVPs were diluted to normalize for 
WNV copy number and BHK-21 cells were infected. Sixteen hours post-infection, cells 
were lysed and luciferase signal was measured. Each bar represents the mean of four 
replicates with error bars showing standard deviation. **p value <0.001, *p value <0.05 
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Resistance of DENV structural protein mutations to 7-148-6 
To examine the effect of E(M196V) and M(H28Y) mutations on sensitivity to 
compound 7-148-6, we normalized inocula by WNV genome copy number and treated 
RVPs with 7-148-6 prior to cell infection. Wild-type RVPs treated with 7-148-6 showed 
a significant decrease in luciferase signal when cells were lysed 16 hours post-infection 
and compared to DMSO-treated RVP signal (Figure 4-8). The luciferase signal produced 
by cells infected with E(M196V) RVPs did not decrease when RVPs were pre-treated 
with 7-148-6, indicating that E(M196V) confers resistance to 7-148-6. M(H28Y) RVPs 
did not have a significant decrease in luciferase signal after 7-148-6 treatment either, 
although the low overall luciferase activity of this mutant makes this result difficult to 
interpret.  
These results suggest that the E(M196V) change may be responsible for the 
insensitivity of our passaged virus to the presence of 7-148-6. It is possible that M(H28Y) 
also contributes to resistance, and in the authentic virion, both mutations may contribute 
to resistance to 7-148-6. These data show that a single point mutation in the DENV E 
protein, even a conservative one from methionine to valine, enhances DENV entry and 
may alter sensitivity to a small molecule entry inhibitor. 
 
Probing DENV envelope protein changes with single-cycle infection reporter virus 
  Serially passaging DENV in the presence of ten compounds revealed outgrowth 
of only one resistant virus. This suggests that it may be difficult for DENV to overcome 
the presence of small molecule entry inhibitors, possibly because any mutations that 
confer resistance may come at a high fitness cost for the virus. Since E(M196V) is    117 
 
Figure 4-8. RVPs with DENV structural protein changes show decreased sensitivity 
to compound 7-148-6. Recombinant viral particles (RVPs) encoding wildtype structural 
proteins, E(M196V), or M(H28Y) mutant proteins were diluted to normalize for genome 
copy and subsequently used to infect BHK-21 cells after pre-treatment with 10 µM 
compound 7-148-6. Cells were lysed 16 hours post-infection, and luciferase signal was 
measured. Each bar represents the mean of four replicates with error bars showing 
standard deviation. *p value < 0.05 
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located at the base of the BOG pocket, an area of the protein thought to act as a “hinge 
region” for the large conformational change of E as it mediates membrane fusion (Modis 
et al., 2003), we wanted to probe the tolerance of substitutions in this region more 
directly. Using site-directed mutagenesis of the plasmid encoding the DENV structural 
genes (the “CprME plasmid”), we mutated each of eleven selected amino acids to alanine 
and tested production and entry in the RVP system (Figure 4-9). The chosen residues 
were selected due to either conservation among DENV serotypes or previous implication 
in altering the optimal pH of fusion, and mapped to three regions of the BOG pocket. 
Three residues, Q52, V130, and Q131 are clustered around the bottom outer edge of the 
pocket. V130 is conserved across DENV serotypes, while both Q52 and Q131 have been 
previously implicated to alter the optimal pH of fusion (Modis et al., 2003). Another four 
residues, D192, F193, N194, and M196 are found in a sequence, 
192DFNEM
196, which is 
conserved across DENV serotypes; these residues form the bottom of the BOG pocket 
and sit close to the lipid membrane of the virion. This region forms a pseudo-alpha helix 
that may make inter-trimer contacts in the post-fusion trimer structure (Modis et al., 
2004) and, outside of the fusion loop, is one of the largest stretches of conserved amino 
acids in the DENV envelope protein. M196 is also the residue altered to valine in the 
passaging of DENV in the presence of 7-148-6, and we were curious to determine the 
effect of an alanine at this position. The final set of amino acids chosen, G275, L277, 
L278, and F279 are not part of the pocket itself, but rather located on the k-l loop that 
covers the opening of the pocket. G275, L277, and F279 are conserved across DENV 
serotypes, while F279 has also been suggested to alter optimal pH of fusion (Lee et al., 
1997).   119 
 
 
 
Figure 4-9. Location of selected residues for mutagenesis on the DENV2 envelope 
crystal structure. Crystal structure of DENV envelope protein (Modis et al., 2003). 
(Top) Pre-fusion DENV E dimer. Each inset focuses on a group of amino acids selected 
for mutagenesis. (Middle left) Q52, V130, and Q131, all located near the front and 
bottom of the BOG pocket. (Middle right) D192, F193, N194, and M196, part of the 
chain that forms the bottom of the BOG pocket (Bottom) G275, L277, L278, F279, all 
located on the k-l loop.   120 
We mutated each residue to an alanine in the CprME plasmid and used these 
plasmids to transfect cells to produce RVPs. RVP preparations were titered by 
quantifying the number of WNV genomes/mL present in serial dilutions of producer cell 
supernatant. We graphed this value against luciferase activity detected in target cells 16 
hours post-infection, allowing us to draw a picture of the effect of mutations on both RVP 
production and entry (Figure 4-10). We found that three mutations, V130A, N194A, and 
L277A, had detectable levels of WNV genomes in producer cell supernatant but low 
luciferase activity in target cells. This suggests that these changes may have a detrimental 
effect on RVP entry. In contrast, mutation to an alanine at positions 193 or 279, originally 
phenylalanines, caused low luciferase activity in RVP target cells but also near 
undetectable levels of WNV genomes in producer cell supernatant, suggesting these 
change may impact production of RVPs. 
The methionine to valine and methionine to alanine mutations at position 196 
differed in their qualitative effects on RVP entry, which may suggest that loss of 
hydrophobic bulk at this site has a deleterious effect on this viral process. While more 
extensive mutagenesis of this region is necessary to validate this hypothesis, our current 
results demonstrate that mutations in the E protein “hinge region” can affect both 
production and entry of virus particles.  
 
Changes in the DI/DII region may affect sensitivity to small molecule entry 
inhibitors 
We selected two mutations, Q52A and Q131A, from our RVP screen to test 
against small molecule entry inhibitors to determine if these changes conferred resistance.    121 
 
Figure 4-10. Changes in the DENV E protein DI/DII interface affect production and 
entry of RVPs. RVPs with alanines introduced at select locations were produced and 
qRT-PCR was performed on serial dilutions to determine RVP production (x axis). 
Serially diluted supernatants were used to infect BHK-21 cells, and lysate was collected 
16 hours post-infection to detect luciferase activity as a measure of RVP entry (y axis). 
Each point represents the mean of four replicates with error bars showing standard 
deviation. 
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Examination of our RVP screen suggested that these two mutants may enter cells more 
efficiently than the wild-type, a phenotype similar to that of E(M196V). Thus, we 
hypothesized that the increased infectivity of Q52A and Q131A might also be associated 
with resistance to our compounds. 
As we had done for E(M196V) and M(H28Y), we first measured E(Q52A) and 
E(Q131A) RVP production by quantifying WNV genome in producer cell supernatant 
(Figure 4-11A). We found that production of E(Q52A) RVPs was significantly reduced 
compared to wild-type RVPs. However, when we measured luciferase activity after 
normalizing to genome number, we found that E(Q52A) RVPs actually had a significant 
increase in luciferase signal (Figure 4-11B). These results suggest that the E(Q52A) 
mutation may have a negative impact on viral particle production but enhance viral entry. 
We next normalized to WNV genome copy number in the supernatant and treated 
RVPs with 7-148-6, 2-12-2, or GNF-2 prior to infecting target cells. Treatment of wild-
type RVPs by each compound led to significant decreases of luciferase activity in target 
cells compared to a DMSO-treated control (Figure 4-12). In contrast, we found no 
significant decrease in either E(Q52A) or E(Q131A) RVPs when treated with any of 
these compounds. This suggests that these individual mutations may decrease sensitivity 
of the RVPs to compound inhibition. 
 
DISCUSSION 
This chapter describes our investigation of effects of point mutations in the 
DENV E protein on viral entry and sensitivity to a subset of our small molecule entry 
inhibitors. Passaging of DENV2 in the presence of small molecules led to outgrowth of    123 
 
 
Figure 4-11. DENV envelope protein mutations affect virus particle production and 
entry in a single-cycle infection assay. (A) RVPs in producer cell supernatant were 
quantified by performing qRT-PCR against the WNV replicon. Each bar represents the 
mean of three replicates with error bars showing standard deviation. (B) After 
quantification, RVPs were diluted to normalize for WNV copy number and BHK-21 cells 
were infected. Sixteen hours post-infection, cells were lysed and luciferase signal was 
measured. Each bar represents the mean of four replicates with error bars showing 
standard deviation. *p value <.0.05 
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Figure 4-12. E(Q52A) and E(Q131A) may confer resistance to small molecule entry 
inhibitors. RVPs containing wild-type E, E(Q52A), or E(Q131A) were diluted to 
normalize for genome copy and pre-treated with the indicated compounds at their 
previously calculated EC90 values against DENV2 (MOI of 1) before addition to cells. 
Cells were lysed 16 hours post-infection and luciferase signal was measured. Each bar 
represents the mean of four replicates with error bars showing standard deviation.  
*p value < 0.01 
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virus against only one out of ten small molecule, 7-148-6, suggesting that DENV does 
not easily escape the presence of the compounds. Consistent with this hypothesis are the 
results of our small alanine mutagenesis screen, in which eight of eleven mutations in the 
domain I/II interface of E drastically reduced viral particle production or entry.  
  Sequencing of DENV2 passaged in the presence of 7-148-6 identified two 
mutations that caused changes in the E and M proteins, the structural proteins on the 
virion surface. Characterization of the E(M196V) and M(H28Y) mutations in a single-
cycle reporter virus assay suggests that these changes impact viral particle entry. 
E(M196V) enhanced entry of reporter virus particles and caused insensitivity to the 
compound 7-148-6, against which it was selected. M(H28Y) may also confer some 
degree of resistance to 7-148-6, although the marked decrease in entry of these virus 
particles makes this difficult to interpret. Despite the full recovery of entry signal in 
E(M196V) RVPs after treatment with 7-148-6, it is probable that this single E protein 
residue does not solely dictate compound sensitivity. This is due to the fact that the 
methionine at position 196 is conserved across all DENV serotypes, yet 7-148-6 did not 
inhibit DENV3 or DENV4, suggesting that other amino acids play a factor in the antiviral 
activity of 7-148-6. 
We showed that compound 7-148-6 likely has a viral target, is active during 
DENV entry, and blocks DENV2 fusion in vitro. The results with E(M196V) RVPs are 
consistent with the hypothesis that 7-148-6’s target is the E protein on the surface of the 
virion. At this point, it is unclear how the E(M196V) change causes resistance to 7-148-6. 
While escape mutations on proteins have traditionally been useful in inferring the binding 
sites of antivirals on their respective targets, it is unclear if the M196V change inhibits   126 
binding of the compound directly or if it allows for escape by altering how the E protein 
mediates fusion or undergoes the conformational rearrangements that occur during fusion. 
The E(M196V) change could impact fusion in a number of ways. Residue 196 is 
located at the base of the BOG pocket, in a position that may make contact with the lipid 
membrane of the virion; it is possible that the shorter side chain of valine at this position 
allows for easier movement of domain II away from the lipid membrane. Another 
possible hypothesis to explain enhanced virus entry or compound resistance is a mutation 
at this position could affect the formation or stability of the E trimer, as the pseudo-alpha 
helix (residues 192-196) is predicted to make intra-trimer contacts in the final post-fusion 
E structure. This hypothesis could also explain why the M196A change resulted in 
reduced entry of RVPs, as the smaller side chain of alanine could have a detrimental 
effect on trimer formation or stability. Alternatively, it is possible that the M196V change 
directly affects the ability of 7-148-6 to bind to the E protein. Our laboratory is currently 
performing studies with recombinant dengue envelope protein to test this possibility. 
  The other identified change in the structural proteins of DENV was a histidine to 
tyrosine change located in the ectodomain of the M protein, a mutation that significantly 
reduced RVP entry. On its own, it is unclear how this change affects entry or could 
confer resistance to 7-148-6. Little is known about what role, if any, the M protein plays 
in DENV infectivity after the pr peptide is cleaved (Mukhopadhyay et al, 2005). One 
study showed that, post-cleavage, the ectodomain of M rests partially buried in the virus 
lipid envelope underneath the E protein homodimer (Kuhn et al., 2002). It is possible that 
M makes contacts with E and could influence movement of domain II away from the 
viral membrane. It is also possible that M(H28Y) appeared in passaged DENV2 as a   127 
compensatory mutation for E(M196V). One way to test this hypothesis would be to 
examine entry and compound sensitivity of RVPs that contain both E(M196V) and 
M(H28Y), experiments that we are currently performing. 
  The alanine mutagenesis screen of the BOG pocket on the E protein was 
performed to examine the effects of mutations in this region on viral entry. The majority 
of mutations we introduced appeared to affect viral particle production and/or entry, 
suggesting that changes in this region may have a fitness cost for the virus. Unfortunately, 
due to our inability to monitor the presence of E protein release into producer cell 
supernatant, we cannot rule out the possibility that some point mutations that appear to 
affect viral particle production or release may, in fact, have interfered with earlier steps of 
the DENV life cycle such as production of E or coating of immature viral particles 
The contrasting results of E(M196V) and E(M196A) in the RVP system suggest 
that specific substitutions may dictate the effect of mutations in E on viral entry, making 
it difficult to draw conclusions from our limited mutagenesis screen about the 
contribution of specific residues. In order to better understand potential mechanisms of 
resistance and the impact of resistance mutations on fitness, additional mutagenesis 
experiments should be performed targeting residues in this region that are not conserved 
or that have not been implicated in altering the pH of viral fusion. 
  A recently published study reported site-directed mutagenesis of several residues 
around the BOG pocket in authentic DENV and, similar to our results, found that many 
of their mutations had effects on DENV entry or viability (Butrapet et al., 2011). Two 
mutations in their study, F193A and F279A, were identical to mutations that we 
examined in the RVP system. The E(F193A) mutant virus was found to have lower   128 
replication efficiency while the E(F279A) mutant virus exhibited no change in the pH 
threshold of fusion or in viral replication, although this mutant virus was found after 
several passages to have a mixed population of alanine and leucine at position 279. In the 
RVP system, we found that both of these mutations inhibited RVP production and would 
be expected to cause reduced viral replication in the context of the authentic virus. 
However, since the RVP system permits only single-cycle infection, it does not allow for 
compensatory or reversion mutants, and this may provide a possible explanation for 
apparent discrepancies between our study and the previous results using authentic virus. 
   Interestingly, Butrapet et al. (2011) also mutated Q52, although to an arginine 
instead of alanine. In RVPs, we found that Q52A caused a significant inhibition of viral 
particle production, but when normalized for WNV genome copy, significantly increased 
RVP entry (Figure 4-11). In authentic virus, Butrapet et al found that Q52R caused 
increased cytopathic effect upon passaging in cells and possibly a higher pH threshold for 
fusion. An explanation consistent with both sets of results is that mutations at residue 52 
lead to enhancement of DENV fusion. 
  We tested E(Q52A) and E(Q131A) against a subset of our small molecule entry 
inhibitors and found that both changes conferred resistance to all three compounds 
compared to wild-type RVPs. As with E(M196V), we do not currently know how these 
changes confer resistance. Residues 52 and 131 are located close to the mouth of the 
BOG pocket, while 196 sits at the very base (Figure 4-9), making it unlikely that all three 
changes inhibit binding of small molecules. A more likely explanation is that one or more 
of these changes alter DENV fusion as a means of escaping small molecule inhibition.   129 
In the work presented here, we have begun to explore how changes to the DENV 
E protein influence both the entry of virus particles as well as susceptibility to small 
molecule entry inhibitors. We identified a point mutation in the envelope protein, 
E(M196V) that rendered a single-cycle reporter virus insensitive to the presence of the 
compound it was raised against. This is the first recorded instance of a potential 
resistance mutation to a DENV small molecule entry inhibitor. However, further work 
should be done to characterize this resistance mutation as well as explore the mechanism 
of resistance. The mutation should be introduced back into authentic dengue virions, 
which would allow for biochemical studies to examine DENV fusion in the presence or 
absence of 7-148-6. In addition, we show that specific substitutions in the hinge region of 
E can impact viral particle production or entry. These results provide promising leads to 
learn more about the molecular interaction of our DENV small molecule entry inhibitors 
with the E protein as well as to discover more about the functional contribution of 
individual amino acids in the E protein to DENV fusion. 
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METHODS AND MATERIALS 
DENV passaging 
Initially, DENV2 (MOI 0.1) was incubated with selected compounds (see text) for 45 
minutes at 37°C before addition to 10
6 Vero cells in a T25 flask. After a one hour 
infection, 5 ml medium was added (2% FBS in DMEM) containing compound or DMSO. 
Infections proceeded for four days, at which point supernatant was harvested and spun 
briefly to remove cell debris. Five hundred µL of supernatant was used to infect a fresh 
T25 of Vero for one hour, at which point 4.5 ml of medium containing compound was 
added. Viral titer of each passage was determined by plaque-forming assay. The first 
passaging with compounds maintained 20 µM of each compound over eight passages. 
The second passaging started at 2.5 µM and increased by 2.5 µM each passage until 20 
µM was reached, which was kept constant for two passages. 
Order of addition experiments 
DENV2 (NGC strain) was used to infect BHK-21 cells at an MOI of 1 for all 
experiments. Compound was used at 10 µM. Virus was pre-incubated in 100 !L of 
medium containing compound at 37°C. For co-infection, 10 !M of compound or DMSO 
was added to virus inoculum directly before addition to cells. After an initial one hour 
infection, cells were washed twice with 1X PBS to remove unbound compound and virus, 
and 1 mL cell medium (MEM-alpha with 2% FBS) was added. For post-treatment of 
cells, compound was added to medium for 1 hour post-infection at 10 µM, then removed 
and cells were washed twice and medium was replaced. Twenty-four hours after initial 
infection, supernatant was collected and viral titer was determined by plaque-forming 
assay.    131 
Removal of unbound compounds by gel filtration column 
DENV2 (NGC strain) inocula (MOI 2) was pre-incubated in 100 !L with 10 !M of 
compound or DMSO for 45 minutes at 37°C, then placed over a Sephadex G50 spin 
column and spun for 2 minutes at 2000 rpm at room temperature. Eluant was used to 
infect cells for 1 hour, after which cells were washed twice with 1X PBS to remove 
unbound compound and virus, and 1 mL cell medium (MEM-alpha with 2% FBS) was 
added. Twenty-four hours after initial infection, supernatant was collected, and viral titer 
was determined by plaque-forming assay.  
DENV attachment to cells 
DENV2 (NGC strain) was incubated with either 5 !M of 2-12-2 or 8-24-3, 20 !g/ml of 
heparin, or DMSO for 45 minutes at 37°C, then added to BHK cells (MOI 1) at 4°C for 
one hour with constant rocking. Cells were washed three times with cold 1X PBS to 
remove unbound virus or compound. For quantitation of viral genomes bound, total RNA 
was extracted using Trizol according to manufacturer’s instructions and qRT-PCR was 
performed. For viral yield determination, one mL of medium was added (MEM-alpha 
with 2% FBS), and culture supernatant was harvested 24 hours later. To determine viral 
titer in supernatant, plaque-forming assays were performed. 
Quantification of DENV genomes 
Quantification of DENV genomes was done on a MyIQ Cycler (Biorad). After RNA 
extraction and quantification, 5 !L of RNA was used to make cDNA with the iScript kit 
(Biorad) according to manufacturer’s instructions. The resulting cDNA was digested by 
RNaseH for 1 hour at 37°C. Quantification by rt-PCR was done on each sample in   132 
triplicate (25 !L each) using SybrGreen Supermix (Biorad) according to manufacturer’s 
instructions. Primers used targeted the DENV C gene.  
DV2Cfor  5’-AATATGCTGAAACGCGAGAGA-3’  
DV2Crev  5’-GGGATTGTTAGGAAACGAAGG-3’ 
Liposomes 
Liposomes were made with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) (Avanti Polar Lipids 
cat # 850457 and 850757, respectively), and cholesterol (Sigma-Aldrich cat#C3045) at 
1:1:2 molar ratio in TAN buffer (20mM triethanolamine, 100mM NaCl, pH 8.0). Lipids 
were dried down and resuspended thoroughly by vortexing and sonication. Liposomes 
were prepared by extrusion through a 0.2 micron filter after five freeze/thaw cycles. For 
trypsin-containing liposomes, 10 mg of trypsin was added to 1 mL of lipids (3 mg each) 
after the third freeze/thaw cycle, prior to extrusion. Liposomes were separated from 
unincorporated trypsin by size-exclusion chromatography using a Superdex 200 column 
on an Akta fast performance liquid chromatography (FPLC) system. Trypsin-containing 
liposomes were used within 24 hours. 
Capsid protection assay 
Purified dengue 2 virus (300 ng) was incubated with various concentrations of 
compounds (5-40 !M) for 45 minutes at 37°C in TAN buffer (pH 8.0) prior to addition of 
liposomes (7.5 !L of peak fraction from column) for ten minutes. After incubation with 
liposomes, 7.5 !L 1M sodium acetate (pH 5.0) was added to drop pH to 5.5 for ten 
minutes. Samples were back-neutralized with 15 !L 1M TEA (unbuffered) and incubated 
for forty-five minutes at 37°C to allow trypsin digestion (total volume: 100 !L). SDS   133 
sample buffer (20 !L) was added, and samples were boiled for 20 minutes before being 
separated by SDS-PAGE on a 12% gel. Proteins were transferred to a nitrocellulose 
membrane using a semi-dry transfer. 4G2 antibody, grown in house from ATCC cell line 
HB-112, was used for detection of DENV envelope (dilution varies by lot), and the neat 
supernatant of hybridoma cell line 6F3.1, kindly provided by Dr. John Aaskov, was used 
to detect capsid protein. 
Production of recombinant virus particles 
Plasmids for WNV replicon and DENV structural proteins were the kind gift of Dr. Ted 
Pierson. RVP production was performed according to protocols received from his lab 
(Ansarah-Sobrinho et al, 2008). 293T-LX cells were transfected with plasmids using 
Lipofectamine 2000 according to manufacturer’s instructions at a ratio of 3:1 (DENV 
CprME:WNV replicon). Medium was changed 4 hours post-transfection and supernatant 
was collected at 25 hours post-transfection. Supernatant was spun for 5 minutes at 1200 
rpm to remove cell debris and was put through a 0.2 micron filter before freezing. Viral 
RNA was extracted using the QIAamp Viral RNA kit according to manufacturer’s 
instructions. RNA was transcribed to cDNA using iScript cDNA kit (Biorad) according 
to manufacturer’s instructions and qPCR was performed using primers against the WNV 
replicon to quantify genome copies. 
Quantification of WNV replicon 
Quantification of WNV replicons in RVP supernatant was done on a MyIQ Cycler 
(Biorad). RVP RNA was extracted using the QIAamp Viral RNA Mini kit from Qiagen 
(Cat#52906) and suspended in a final volume of 60 !L, 2 !L of which was used to make 
cDNA with the iScript kit (Biorad) according to manufacturer’s instructions. The   134 
resulting cDNA was digested by RNaseH for 1 hour at 37°C. Quantification by rt-PCR 
was done on each sample in triplicate (25 !L/well) using SybrGreen Supermix (Biorad) 
according to manufacturer’s instructions. Sequences of primers against the WNV 3’ UTR 
replicon are listed below. 
WNVfwd:  5’-AGAGTGCAGTCTGCGATAGTGC-3’  
WNVrev:  5’-CCCTTCTCCCTGGTTAACA-3’ 
Site-directed mutagenesis of DENV CprME plasmid 
Site-directed mutagenesis of the DENV CprME plasmid was performed using the 
Stratagene Quikchange II kit according to manufacturer’s instructions (Cat#200518). 
Primers to introduce all mutations were designed using the Quikchange Primer Design 
website (sequences listed below). XL10 Gold competent cells were transformed with 
mutated plasmids after digestion and grown at 30°C for 2 days. Selected colonies were 
grown in superbroth at 30°C for 24 hours, then plasmids were isolated and sequenced to 
confirm the presence of mutations. 
M(H28Y): c1652t 5'-cagaaggggcctggaaatatgtccagagaattga-3'; c1652t_antisense 5'-
tcaattctctggacatatttccaggccccttctg-3' 
E(M196V): a2381g 5'-gcctcgacttcaatgaggtggtgttgttgcagatg-3'; a2381g_antisense 5'-
catctgcaacaacaccacctcattgaagtcgaggc-3' 
E(Q52A): c1949g_a1950c 5'-tgaactgataaaaacagaagccaaagcgcctgccacccta-3'; 
c1949g_a1950c_antisense 5'-tagggtggcaggcgctttggcttctgtttttatcagttca-3' 
E(V130A): t2184c 5'-gaacatggaaggaaaagttgcgcaaccagaaaacttggaat-3'; t2184c_antisense 
5'-attccaagttttctggttgcgcaacttttccttccatgttc-3'   135 
E(Q131A): c2186g_a2187c 5'-gaacatggaaggaaaagttgtggcaccagaaaacttggaatacacc-3'; 
c2186g_a2187c_antisense 5'-ggtgtattccaagttttctggtgccacaacttttccttccatgttc-3' 
E(D192A): a2370c 5'-ccaagaacgggcctcgccttcaatgagatggtg-3'; a2370c_antisense 5'-
caccatctcattgaaggcgaggcccgttcttgg-3' 
E(F193A): t2372g_t2373c 5'-ccaagaacgggcctcgacgccaatgagatggtgttgtt-3'; 
t2372g_t2373c_antisense 5'-aacaacaccatctcattggcgtcgaggcccgttcttgg-3' 
E(N194A): a2375g_a2376c 5'-gaacgggcctcgacttcgctgagatggtgttgttgc-3'; 
a2375g_a2376c_antisense 5'-gcaacaacaccatctcagcgaagtcgaggcccgttc-3' 
E(M196A): a2381g_t2382c 5'-ggcctcgacttcaatgaggcggtgttgttgcagatgga-3'; 
a2381g_t2382c_antisense 5'-tccatctgcaacaacaccgcctcattgaagtcgaggcc-3' 
E(G275A): g2619c 5'-agaaatccaaatgtcatcagcaaacttactcttcacaggac-3'; g2619c_antisense 5'-
gtcctgtgaagagtaagtttgctgatgacatttggatttct-3' 
E(L277A): t2624g_t2625c 5'-aatccaaatgtcatcaggaaacgcactcttcacaggacatctcaag-3'; 
t2624g_t2625c_antisense 5'-cttgagatgtcctgtgaagagtgcgtttcctgatgacatttggatt-3' 
E(L278A): c2627g_t2628c 5'-cagaaatccaaatgtcatcaggaaacttagccttcacaggacatctc-3'; 
c2627g_t2628c_antisense 5'-gagatgtcctgtgaaggctaagtttcctgatgacatttggatttctg-3' 
E(F279A): t2630g_t2631c 5'-gtcatcaggaaacttactcgccacaggacatctcaagtgc-3'; 
t2630g_t2631c_antisense 5'-gcacttgagatgtcctgtggcgagtaagtttcctgatgac-3' 
RVP infection of cells 
RVPs were used to infect BHK-21 cells in 48-well plates. RVPs were diluted to 10
5 
genomes/mL and incubated with small molecules at their respective EC90 values (as 
determined in cellular entry assays) for 45 minutes at 37°C. This mixture was added to 
cells for a one hour initial infection (37°C), after which cells were washed twice with 1X   136 
PBS. All infections were done in quadruplicate. Medium was added (2% FBS in MEM-
alpha) and cells were incubated at 37°C for 16 hours. At 16 hours post-infection, cells 
were washed once before lysis and lysate was moved to -20°C until use. Luciferase signal 
was determined with a Renilla luciferase activity kit (Promega Cat#E2820).  
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Chapter 5: Discussion 
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SUMMARY 
  The project covered in this dissertation stems from an unexpected observation: 
namely, that DENV yield was lowered when initial virus inoculum was pre-incubated 
with GNF-2, a previously identified small molecule inhibitor of intracellular Abl kinases. 
This discovery serves as a reminder of the importance of exploring the possibility of off-
target effects for many scientific approaches, from RNAi to small molecules to peptides.  
Chapter 2 discusses our initial observation of an unexpected drop in DENV yield 
when virus inoculum is pre-incubated with a small molecule inhibitor of cellular Abl 
kinases, GNF-2. Further experiments revealed that GNF-2 interacts with purified DENV 
virions as well as recombinant envelope protein dimer, the pre-fusion form of the 
envelope found on the surface of mature visions. Other small molecule inhibitors have 
previously been reported to interact with dengue, but these were discovered through high-
throughput and in silico screens designed to identify compounds that bind directly to the 
envelope protein of the virion (Kampmann et al., 2009; Poh et al., 2009; Schmidt et al., 
2012; Wang et al., 2009; Zhou et al., 2008). In contrast, GNF-2 is well established as an 
inhibitor of Abl kinases that derives its high degree of selectivity by binding in the 
myristate-binding pocket of the kinase and is inactive against over 450 other cellular 
kinases (Adrian et al., 2006; Zhang et al., 2010). Our discovery that GNF-2 inhibits 
DENV at two separate points in the viral life cycle raises the intriguing possibility of 
designing small molecule inhibitors that block viruses via two targets at separate points 
during the viral life cycle. 
As a way to separate GNF-2’s two anti-DENV activities – one mediated by 
intracellular Abl kinase and one mediated by interactions with the dengue virion – we   141 
performed a structure-activity relationship study in collaboration with Dr. Nathanael 
Gray’s laboratory. This led to the identification of twenty-three small molecules that 
inhibited DENV infectivity with equivalent or improved activity relative to GNF-2. All 
twenty-three molecules showed no inhibition of Abl kinases in cellular assays. In Chapter 
3, we selected two of these compounds for further characterization. We found that DENV 
yield was not inhibited if virus is pre-incubated with compound at 4°C, suggesting 
dynamic motion of the virion surface may be necessary to allow binding of compounds. 
When we examined specific steps of the DENV entry process, we found that the 
compounds did not inhibit attachment of virions to cells, but did prevent completion of 
viral fusion in vitro. These results are consistent with our current hypothesis that the 
small molecule inhibitors interfere with the significant structural changes that the DENV 
E protein must undergo during viral entry, although additional experiments are needed to 
provide support for and refine this hypothesis. The SAR study and mechanistic work that 
I have presented add to the growing body of identified DENV entry inhibitors that 
prevent viral fusion. 
In Chapter 4, we utilized a classical virology approach to learn more about the 
mechanism of action of our DENV entry inhibitors. We passaged virus in the presence of 
ten compounds, and observed outgrowth of an insensitive virus against only one, 7-148-
6. Sequencing of the structural genes of this virus quasispecies revealed two point 
mutations; one each in the E and M proteins. Using a single-cycle reporter virus assay, 
we found that treatment of wild-type virus particles with 7-148-6 reduced viral entry, but 
no drop was observed with virus particles containing the E(M19V) or M(H28Y) 
mutation, suggesting that both changes may play a role in the observed resistance of the   142 
authentic virus. We then performed an alanine scanning study focused on the region 
surrounding the E(M196V) mutation and, using the single-cycle reporter virus, found that 
the majority of point mutations in this area were not well-tolerated, decreasing either viral 
particle production or entry. Two mutations, E(Q52A) and E(Q131A), showed efficient 
virus entry and were subsequently tested against a subset of our small molecule entry 
inhibitors. Both mutations exhibited reduced sensitivity to all three small molecules 
tested when compared to the compounds’ effect on wild-type virus particles. 
Interestingly, the E(M196V), E(Q52A), and E(Q131A) reporter viruses all had higher 
infectivity than wild type viruses, as reflected by luciferase signal per genome copy. This 
possible enhancement of viral entry may explain the reduced sensitivity to compounds. 
Alternatively, reduced sensitivity to the entry inhibitors may indicate that the E protein 
mutations interfere with the interaction of compounds with E. Additional experiments 
that elucidate not only the interactions mediating binding of the inhibitors to wild-type 
and mutant E proteins but also the mechanism(s) of action of our entry inhibitors are 
needed to distinguish between these two potential mechanisms of resistance, which are 
not mutually exclusive. Our current results suggest that point mutations in the E domain 
I/II interface may affect sensitivity to entry inhibitors and supports previous work that 
individual residues in this region can impact DENV entry.  
   
DISCUSSION AND FUTURE DIRECTIONS 
The need for DENV therapeutics is undeniable; cases of DENV fever and severe 
fever have increased exponentially over the past four decades and there are still no 
specific vaccines or treatments available (WHO, 2012). However, the search for effective   143 
antivirals is hampered by a lack of understanding of many of the basic viral processes 
that DENV undergoes as well as what cellular proteins are critical for viral infection. 
Until recently, the virus was endemic largely in countries that did not have resources to 
devote to basic research of the virus (WHO, 2012). The reason for the initial screen that 
led to this dissertation and identified GNF-2 as an inhibitor of DENV was to identify 
cellular kinases critical for DENV infection (Chu and Yang, 2007). While a long-term 
goal of our work is to contribute to the search for effective antivirals, a more immediate 
goal is to investigate the DENV life cycle to identify molecules and processes that may 
be pharmacologically targeted to inhibit the virus. 
DENV entry as an antiviral target  
Dengue virus encodes only a small number of viral proteins, thus making it highly 
dependent upon host cells to successfully complete a life cycle. In order to take 
advantage of the host cell machinery, DENV must first enter cells to gain access to the 
host cytoplasm, where viral transcription and replication occur. DENV is taken up into 
cells via clathrin-mediated endocytosis (Acosta et al., 2008; van der Schaar et al., 2008). 
It is then trafficked to cellular endosomes, where exposure to the low pH triggers viral 
fusion with the cellular membrane (Stiasny and Heinz, 2006; van der Schaar et al., 2008). 
Following viral protein production and genome replication, nascent virions are 
assembled, packaged, and undergo maturation during exocytosis prior to the start of a 
new round of infection. 
Each step in the viral life cycle presents a potential point for therapeutic 
intervention, but viral entry may be considered particularly appealing for several reasons. 
DENV entry is a discrete process and, relative to other viral processes such as replication   144 
or assembly, may be of limited scope in terms of viral and cellular proteins involved. In 
addition, the initial interaction between virus and cell occurs on the cell exterior, allowing 
the virion to be targeted by non-cell permeable inhibitors or even antibodies. Finally, 
viral entry occurs prior to genome replication, thereby decreasing the opportunity for 
viral resistance to emerge. 
Limitations of GNF-2 and current inhibitors as potential antivirals 
Importantly, our discovery that GNF-2 and the derivatives identified in the 
structure-activity relationship (SAR) study (Appendix A) inhibit DENV entry does not 
automatically qualify them as promising DENV therapeutics. One limitation of the 
compounds we identified is that none of them potently inhibited all four DENV 
serotypes. During a DENV outbreak, it can initially be unclear which serotype or 
serotypes are circulating, and thus it would be desirable for therapeutics to be active 
against all four serotypes. It is important to note that our efforts in the SAR study were 
directed at optimizing inhibition of DENV2 and only tested against other serotypes after 
potency of DENV2 inhibition was determined. Even with the focus on DENV2, we were 
able to identify five compounds that had measurable EC90 values against all four 
serotypes, suggesting that identification of pan-serotype inhibitors may be possible. A 
second limitation to the direct development of inhibitors such as 2-12-2, 7-148-6, and 8-
24-3 as antivirals is that their potency may be too low (EC90 values in the low single-digit 
micromolar) to be useful antivirals in vivo. While this could be unequivocally established 
via testing in an available animal model of DENV infection (Zompi and Harris, 2012), it 
is likely that additional optimization of inhibitor potency would be necessary to achieve 
therapeutically beneficial inhibition of DENV in vivo.   145 
We are not the first group to identify small molecule inhibitors of DENV entry. 
GNF-2 and the other twenty-one small molecules identified in this study add to the 
growing body of DENV entry inhibitors that purportedly act by inhibiting viral fusion 
(Table 1-1). Our compounds are not as potent as some other small molecules such as 
NITD6 (reported EC50 value 119 nM) (Wang et al., 2009), 3-110-22 (reported IC90 value 
790 nM) (Schmidt et al., 2012), or peptide inhibitors based on the stem region of E 
(reported EC90 value 1 µM (Schmidt et al., 2010), but they do exhibit potencies 
comparable to or exceeding leading compounds from several other studies, including a 
peptide inhibitor with a reported EC50 value of 10 µM (Hrobowski et al., 2005), small 
molecule A5 (reported EC50 value 4 µM) (Yennamalli et al., 2009), small molecule P02 
(reported EC50 13 µM) (Zhou et al., 2008) and small molecule NITD448 (reported EC50 
value 9.8 µM) (Poh et al., 2009). It is worth noting, however, that we calculated the EC90 
values of our compounds, while most other studies calculated EC50 values of compounds. 
Consequently, direct comparisons of anti-DENV potency must await side-by-side 
comparisons of our compounds with reference compounds from prior studies, as we have 
done with NITD6 (Chapter 2). 
In addition, we note that in our SAR optimization, we utilized a relatively low-
throughput assay measuring differences in DENV yield. In the future, utilization of a 
biochemical assay based on fluorescence polarization measurements to monitor 
interaction of compounds with the soluble pre-fusion E dimer or cellular assays utilizing 
the single-cycle reporter virus system may facilitate broader screening efforts and enable 
more sensitive and quantitative detection of the antiviral activities of the GNF-2-inspired 
entry inhibitors described in this study.   146 
Probing mechanism(s) of action using biochemical assays and mutagenesis 
As with most scientific research, the experiments performed in this dissertation 
raise a number of further questions. While our biochemical in vitro experiments reveal 
that the two tested compounds, 2-12-2 and 8-24-3, prevent the completion of DENV 
fusion, we do not know exactly at what step this block occurs. The compounds could 
prevent lipid mixing between the viral and cellular membranes or they may block at a 
another step, such as the fold-back of the E domain III or final formation of the fusion 
pore (Figure 1-3). It is possible to test whether lipid mixing has occurred in vitro using 
pyrene-labeled virus and liposomes as a target membrane (Schmidt et al., 2010), although 
our attempts at this delicate assay with DENV did not yield sufficient signal to 
confidently detect fusion with untreated wild-type virus. However, if this assay were 
optimized and had increased sensitivity, it may be a viable approach to differentiate 
among these possible inhibitory  mechanisms. 
Another, broader, question about mechanism is whether GNF-2 and other 
compounds that were not tested in Chapters 3 or 4 inhibit the same step of DENV 
entry/fusion as 2-12-2, 8-24-3, and 7-148-6. It remains to be determined whether all of 
the compounds identified in our SAR study bind to the same site on E or inhibit DENV 
entry via the same molecule mechanism It is therefore of interest to use our in vitro 
biochemical fusion assays to test a broader panel of compounds as well as test the above 
compounds against other DENV serotypes. Likewise, efforts to identify the binding 
site(s) of these compounds on the E structure via high-resolution structure determination 
are of considerable interest.   147 
In the meantime, the results from our mutagenesis studies constitute an important 
step towards examining the potential mechanism of action of our DENV entry inhibitors 
while also serving as a broader study of the fusion of this region of the E protein in 
DENV entry. The E protein DI/DII interface has been of great interest to the flavivirus 
field since 2003, when the possibility of inhibiting DENV entry by targeting this region 
with a small molecule was first proposed (Modis et al., 2003). However, little 
experimental work has been done to explore this region outside of using it to model or 
test small molecule inhibitors. One recent study (Butrapet et al., 2011) performed a 
mutational analysis in this region of the protein using reverse genetics and found that in 
Vero cells, eight out of 15 selected residues were either lethal or unstable (i.e., did not 
retain the engineered mutation or contained purported compensatory mutations in other 
locations). These data, along with the RVP results in our studies demonstrating that point 
mutations in the domain I/II interface potentially affect expression, release, and/or entry 
of virus particles, suggest that changes in this area may have wide-ranging effects in the 
DENV life cycle. Further cellular and biochemical experiments are needed to 
characterize the phenotypic block in the DENV life cycle caused by mutations in this 
region of E. Elucidation of the relationship between structure and function of this region 
of the E protein should aid in rational design of either entry inhibitors or antivirals 
targeted to other steps of DENV infection. 
  While our RVP data suggest that the E(M196V) mutation potentially enhances 
viral entry, there are still many unanswered questions about this mutation, both within 
and outside the context of our small molecule inhibitors. Our group is currently working 
to determine whether the E(M196V) mutation alters the ability of recombinant envelope   148 
protein to associate or interact with GNF-2 and other small molecules. This work will 
help clarify how this mutation confers resistance to the small molecule inhibitors; if the 
compound has reduced affinity for the E(M196V) protein, this suggests that resistance is 
conferred by prevention of compound binding. Otherwise, E(M196V) may confer 
resistance by causing E to become hyperfusogenic (Biering et al., 2012; Higgs and 
Gould, 1991) thus allowing the virus to complete fusion despite the presence of the 
compounds. E(M196V) could also alter the optimal pH of fusion, an event that has 
previously been suggested to occur when changes are made in the domain I/II interface 
(Beasley and Aaskov, 2001; Lee et al., 1997), and which could be tested by using virus 
containing this change in the in vitro capsid protection assay, where the pH drop can be 
tightly controlled. These two models are both consistent with our existing data and are 
not mutually exclusive. 
  In addition, we are studying the E(M196V) and M(H28Y) mutations in the 
context of full infectious virus by isolating plaque-purified DENV containing either or 
both mutations. Efforts are underway to measure the effect of these mutations on viral 
infectivity in the presence and absence of small molecule inhibitors and the behavior of 
these mutant viruses in biochemical fusion assays. We hope these results will validate the 
conclusions drawn from our single-cycle reporter virus studies. Likewise, independent 
introduction of these mutations to a molecular clone of DENV via reverse genetics will 
ensure that the phenotypes observed are the consequence of the introduced mutations and 
not due to previously undetected mutations in the DENV genome. 
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  The work presented in this dissertation provides functional confirmation of the 
importance of the DI/DII interface of the E protein in DENV entry and adds to the 
growing body of knowledge of small molecule inhibitors of DENV entry. Although not 
the focus of my dissertation, GNF-2’s inhibition of DENV via two separate targets via 
two independent mechanisms of action is also worthy of note.  The concept of using 
multi-targeted compounds to achieve a maximal therapeutic index is gaining traction in 
other areas of biomedicine, notably oncology (Dar et al., 2012). Our early work with 
GNF-2 provides conceptual support for the development of dual-action, dual-target small 
molecule inhibitors of DENV that may have higher barriers to viral resistance. We found 
that the compounds most likely target the E protein on the surface of the virion and block 
a late stage in the viral fusion cascade. In pursuing further details about how the 
compounds interact with the E protein, we found that single point mutation(s) in the 
envelope protein can confer resistance to the compounds. While we do not yet know the 
mechanism of resistance, our mutational screen of the domain I/II interface of E revealed 
that changes in this area may have drastic effects on not only entry of the virus, but also 
egress or release of virions. Somewhat ironically, while much of the work described in 
this dissertation has been focused towards development of small molecules that act via a 
single target in order to aid our efforts to establish E as a target mediating GNF-2’s 
inhibition of DENV entry, the development of GNF-2 or GNF-2-inspired compounds as 
potential anti-DENV agents might instead aim at optimizing the activity against Abl and 
E simultaneously.   
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APPENDIX A 
 
GNF-2 analogs identified in structure-activity relationship study  
 
Structures, activities, and cytotoxicities of small molecules identified as active against 
DENV2 in cellular assays. EC90 values were determined by a six point titration curve in 
which molecules were pre-incubated with virus inocula; titers were determined by 
plaque- (DENV2) or focus-forming (DENV1, 3, 4) assay. LD90 values were measured by 
ATP quantification with Promega CellTiterGlo kit.   153 
 
DV1 DV2 DV3 DV4
CVM-07-126-2 20 uM 20 uM 5 uM 40 uM 50 uM
CVM-07-148-2 20 uM 15 uM >40 uM 10 uM 80 uM
CVM-07-148-6 7.5 uM 10 uM >40 uM >40 uM 100 uM
CVM-07-127-B 17.5 uM 15 uM 30 uM >40 uM 40 uM
CVM-07-148-9 7.5 uM 25 uM >40 uM 5 uM 80 uM
CVM-07-148-7 4 uM 20 uM 30 uM >40 uM 50 uM
CVM-2-12-2 4 uM 5 uM 5 uM 40 uM 60 uM
CVM-07-148-1 4 uM 17.5 uM >40 uM 10 uM 100 uM
CVM-07-148-8 7.5 uM 10 uM >40 uM 20 uM 100 uM
CVM-07-126-3 3 uM 10 uM >40 uM 40 uM 100 uM
CVM-07-111-1-B 20 uM 15 uM >40 uM 40 uM >100 uM
X= Cl
CVM-07-128-B
3 uM 15 uM 10 uM 10 uM >100 uM
EC90 (µM)
compound ID R1
X= H
LD90 
(µM)  154 
 
 
DV1 DV2 DV3 DV4
CVM-08-24-1 4 uM 4 uM >40 uM 15 uM 50 uM
CVM-08-24-5 1 uM 3 uM >40 uM 15 uM 90 uM
CVM-2-12-3 1 uM 5 uM 40 uM 17.5 uM 100 uM
CVM-07-119-2-B 1 uM 1 uM >40 uM 10 uM 90 uM
CVM-08-24-2 7 uM 17.5 uM >40 uM 35 uM >100 uM
CVM-08-24-4 3 uM 7.5 uM 40 uM 7.5 uM 75 uM
CVM-08-24-3 3 uM 5 uM >40 uM 10 uM 90 uM
EC90 (µM)
LD90 
(µM)
cmpd ID R1
DV1 DV2 DV3 DV4
CVM-1-100-1 20 uM 7.5 uM >40 uM 15 uM 40 uM
EC90 (µM)
cmpd ID R1
LD90 
(µM)  155 
 
 
 
 
 
 
DV1 DV2 DV3 DV4
CVM-2-12-4 1 uM 20 um 30 uM 5 uM >100 uM
CVM-07-120 7 uM 20 uM >40 uM 7.5 uM 75 uM
CVM-2-21-2 3 uM 3 uM >40 uM 30 uM >100 uM
EC90 (µM)
LD90 
(µM)
cmpd ID R1